<SEC-DOCUMENT>0001140361-23-019300.txt : 20230420
<SEC-HEADER>0001140361-23-019300.hdr.sgml : 20230420
<ACCEPTANCE-DATETIME>20230420094149
ACCESSION NUMBER:		0001140361-23-019300
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230418
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230420
DATE AS OF CHANGE:		20230420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FEMASYS INC
		CENTRAL INDEX KEY:			0001339005
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				113713499
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40492
		FILM NUMBER:		23831653

	BUSINESS ADDRESS:	
		STREET 1:		3950 JOHNS CREEK COURT
		STREET 2:		SUITE 100
		CITY:			SUWANEE
		STATE:			GA
		ZIP:			30024
		BUSINESS PHONE:		770-500-3910

	MAIL ADDRESS:	
		STREET 1:		3950 JOHNS CREEK COURT
		STREET 2:		SUITE 100
		CITY:			SUWANEE
		STATE:			GA
		ZIP:			30024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20008824x2_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:femy="http://femasys.com/20230418" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_52abcf78c0504798930b00bc8d1737ac" contextRef="c20230418to20230418" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_3d14ca5a433c404c86a606c38ab05c4d" contextRef="c20230418to20230418">FEMASYS INC</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_24af1c380ae44bd0856779dd5e61a378" contextRef="c20230418to20230418">0001339005</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_061fc63a2fef4a43a00dda4f8cec9231" contextRef="c20230418to20230418">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="femy-20230418.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230418to20230418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001339005</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-18</xbrli:startDate><xbrli:endDate>2023-04-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div><span style="font-size: 14pt;">UNITED





        STATES</span></div>
</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_3c647021cade46af8a79964193c2eb21" contextRef="c20230418to20230418">8-K</ix:nonNumeric></div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date of Report (Date of earliest event reported):</div>

    <div style="text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_15af6706b1594690814dc3201ef1cf64" contextRef="c20230418to20230418" format="ixt:date-monthname-day-year-en">April 18, 2023</ix:nonNumeric></span><br />
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 24pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_3d14ca5a433c404c86a606c38ab05c4d">Femasys Inc.</span><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: top; font-weight: bold; text-align: center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_77736e12ac2c4de7b53e40e220e71e11" contextRef="c20230418to20230418" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_2d7f8bf357f049b7acd1bf9261b5d147" contextRef="c20230418to20230418">001-40492</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_18b3fe7b9a37491fa70112503787a1c7" contextRef="c20230418to20230418">11-3713499</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(State or Other Jurisdiction</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Incorporation)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Commission File Number)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(I.R.S. Employer</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 8pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 51%; vertical-align: top;">
            <div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_884a4941557942a1ba3470453ce9fe1d" contextRef="c20230418to20230418">3950 Johns Creek Court</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_bfb239de31db4307b75e319b7487cab5" contextRef="c20230418to20230418">Suite 100</ix:nonNumeric></div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_d8932f83426e4044abb90fb6d0f5796c" contextRef="c20230418to20230418">Suwanee</ix:nonNumeric>,
                <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_9f7ae5473ef947c7bb889ff35ea80454" contextRef="c20230418to20230418" format="ixt-sec:stateprovnameen">Georgia</ix:nonNumeric></div>
            </div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 48%; vertical-align: bottom; text-align: center;">
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_2f4ecaa164a9494093fb4c947cb51897" contextRef="c20230418to20230418">30024</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 51%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Address of Principal Executive Offices)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_236f184e53ed45ffa1c861107f1ac8da" contextRef="c20230418to20230418">770</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_782c19ef3b9a4a8e92c1f4ddecb12c55" contextRef="c20230418to20230418">500-3910</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Registrant&#8217;s telephone number)</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_717e92c7e24548a1b6bd02a0b748cef2" contextRef="c20230418to20230418" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_05e8ae921f9b489c8c71c357582db30a" contextRef="c20230418to20230418" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_2a9bc928c84f42c8b710efed90971493" contextRef="c20230418to20230418" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_4976e1d201b243cd90f0487fbc02ba50" contextRef="c20230418to20230418" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.9%; vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 1.98%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Trading Symbol(s)</span></div>
          </td>

    <td style="width: 1.98%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.56%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name of each exchange</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.9%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_02ee142125064a74ba08b3ca4f99006d" contextRef="c20230418to20230418">Common Stock, par value $0.001 per value</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1.98%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.58%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8bc4942cc66946dd932bf5524f8ec334" contextRef="c20230418to20230418">FEMY</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1.98%; vertical-align: bottom;">&#160;</td>

    <td style="width: 31.56%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_061fc63a2fef4a43a00dda4f8cec9231">The Nasdaq Stock Market LLC</span><br />
            </div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b&#8211;2 of the
      Securities Exchange Act of 1934.</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company&#160;&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_ea8ee2027cd747b8b5a7cca646c3f8c9" contextRef="c20230418to20230418" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
<div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_4b6e330c8784449ea978dbf6f32f1a15" contextRef="c20230418to20230418" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1.01 &#8211; Entry into a Material Definitive Agreement.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 18, 2023, Femasys Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Securities Purchase Agreement (the &#8220;Purchase
      Agreement&#8221;) with the purchaser identified in the Purchase Agreement (the &#8220;Purchaser&#8221;). The Purchase Agreement provides for the sale and issuance by the Company of an aggregate of: (i) 1,318,000 shares (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Shares</span>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), and (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 1,878,722 shares (the &#8220;Pre-Funded Warrant
      Shares&#8221;) of Common Stock in a registered direct offering (the &#8220;Registered Offering&#8221;), and (iii) a concurrent private placement (the &#8220;Private Placement&#8221; and, together with the Registered Offering, the &#8220;Offering&#8221;) of warrants (the &#8220;Common Warrants&#8221;) to
      purchase up to 3,196,722 shares of Common Stock (the &#8220;Common Warrant Shares&#8221; and together with the Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares and the Common Warrants, the &#8220;Securities&#8221;). The offering price per Share and associated
      Common Warrant is $1.22 and the offering price per Pre-Funded Warrant and associated Common Warrant is $1.2199.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company has also agreed to issue to H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) (or its permitted assignees) placement
      agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase up to 191,803 shares of Common Stock, at an exercise price of $1.525 per share of Common Stock. The Placement Agent Warrants are immediately exercisable and have a term of five years from
      the commencement of the sales pursuant to the Offerings.<br />
    </div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Pre-Funded Warrants are immediately exercisable, have an exercise price of $0.0001 and may be exercised at any time until all of the
      Pre-Funded Warrants are exercised in full. The Common Warrants are immediately exerciseable, have an exercise price per share of $1.095 and have a term of five and one-half years from the date of issuance.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Offering is expected to result in gross proceeds to the Company of approximately $3.9 million. The net proceeds to the Company from
      the offering are expected to be approximately $3.4 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for general corporate
      purposes.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
      indemnification obligations of the Company, other obligations of the parties and termination provisions.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Purchase Agreement, the Company has agreed that (i) it will not conduct any issuances of Common Stock for a period of
      forty-five (45) days and that (ii) it will not enter into a variable rate transaction, in each case for a period of one (1) year following the closing of the offering, subject to certain exceptions as set forth in the Purchase Agreement.</div>

    <div>
<div><br /></div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to an agreement with the Placement Agent, the Placement Agent agreed to serve as the exclusive placement
        agent for the Offering. As compensation for such placement agent services and in addition to the Placement Agent Warrants, the Company has agreed to pay the Placement Agent a total cash fee equal to 7.5% of the aggregate gross proceeds of the
        Offering, a management fee equal to 1.0% of the aggregate gross proceeds of the Offering, a&#160;non-accountable&#160;expense allowance of $75,000 and clearing fees of $15,950.</div>

      <div>&#160;</div>

    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Registered Offering is being made pursuant to a Registration Statement (File No. 333-266001) on Form S-3, which was filed by the
      Company with the Securities and Exchange Commission on on July 1, 2022, and was declared effective on July 12, 2022, and the related prospectus contained therein, dated July 1, 2022 (the &#8220;Base Prospectus&#8221;), and the prospectus supplement, dated April
      18, 2023 (the &#8220;Prospectus Supplement,&#8221; and, together with the Base Prospectus, the &#8220;Prospectus&#8221;).</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The form of Purchase Agreement, the form of Pre-Funded Warrant, the form of Common Warrant and the form of Placement Agent Warrant are
      filed as Exhibits 10.1, 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The above descriptions of the terms of the form of Purchase Agreement, form of Pre-Funded Warrant, form of Common
      Warrant and form of Placement Agent Warrant are qualified in their entirety by reference to such exhibits.</div>

    <div>
      <div><br />
      </div>

      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item. 3.02. Unregistered Sales of Equity Securities</div>

    </div>

    <div>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information contained above in Item 1.01 related to the Private Placement and the issuance of the Placement Agent
        Warrants is hereby incorporated by reference into this Item 3.02. The Common Warrants, the Placement Agent Warrants and the shares of Common Stock issuable upon exercise of the Common Warrants and the Placement Agent Warrants have not been
        registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder.</div>

    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01 &#8211; Other Events.</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company issued a press release announcing the Registered Direct Offering on April 19, 2023. A copy of the press release is attached hereto as Exhibit 99.1
      and is incorporated herein by reference.</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective April 18, 2023, the Company suspended its &#8220;at-the-market&#8221; sales program pursuant to that certain prospectus supplement dated July 12, 2022 and
      equity distribution agreement, dated July 1, 2022 (&#8220;Equity Distribution Agreement&#8221;) and terminated the continuous offering under such prospectus. The Company will not make any sales of its Common Stock pursuant to the Equity Distribution Agreement
      unless and until a new prospectus supplement is filed with the Securities and Exchange Commission; however, the Equity Distribution Agreement remains in full force and effect.</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;Item 9.01 &#8211; Exhibits.</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits:</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following exhibits are filed as part of this report</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12.93%; vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit Number</div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20008824x2_ex4-1.htm">4.1</a></div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Pre-Funded Warrant</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20008824x2_ex4-2.htm">4.2</a></div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Common Stock Warrant</div>
          </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20008824x2_ex4-3.htm">4.3</a></div>
          </td>

    <td rowspan="1" style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td rowspan="1" style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Placement Agent Warrant</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20008824x2_ex5-1.htm">5.1</a></div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opinion of Dechert LLP</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20008824x2_ex10-1.htm">10.1</a></div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Securities Purchase Agreement dated April 18, 2023, between Femasys Inc. and the purchaser</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20008824x2_ex5-1.htm">23.1</a></div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consent of Dechert LLP (included in Exhibit 5.1)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="ny20008824x2_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release dated April 19, 2023</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: top; white-space: nowrap;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
          </td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: top;">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12.93%; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td style="width: 1.54%; vertical-align: bottom;">&#160;</td>

    <td style="width: 85.54%; vertical-align: bottom;">&#160;</td>

  </tr>


</table>
    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
      hereunto duly authorized.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.77%; vertical-align: top;">&#160;</td>

    <td colspan="3" style="width: 50.23%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Femasys, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.77%; vertical-align: top;">&#160;</td>

    <td colspan="3" style="width: 50.23%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.77%; vertical-align: top;">&#160;</td>

    <td colspan="3" style="width: 50.23%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.77%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: April 20, 2023</div>
          </td>

    <td style="width: 2.68%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 0.78%; vertical-align: bottom; border-bottom: #000000 2px solid;">&#160;</td>

    <td style="width: 46.78%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Kathy Lee-Sepsick</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.77%; vertical-align: top;">&#160;</td>

    <td style="width: 2.68%; vertical-align: top;">&#160;</td>

    <td style="width: 0.78%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.78%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Kathy Lee-Sepsick</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.77%; vertical-align: top;">&#160;</td>

    <td style="width: 2.68%; vertical-align: top;">&#160;</td>

    <td style="width: 0.78%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.78%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title: <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Chief Executive Officer</span></div>
          </td>

  </tr>


</table>
    <div>
<div><br /></div>

      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ny20008824x2_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin-top: 0; margin-bottom: 0; margin-left: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><b>Exhibit 4.1</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><b>EXHIBIT A-1</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="text-transform: uppercase"><b>Femasys Inc.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 70%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</font></td>
        <td style="width: 30%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">Issue Date:______, 2023</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">Initial Exercise Date: _______, 2023</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received,
    _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the &#8220;<u>Initial Exercise Date</u>&#8221;)
    and until this Warrant is exercised in full (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Femasys Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares (as subject to adjustment hereunder, the
    &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><u>Section 1</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Definitions</u>. Capitalized terms used and not otherwise defined herein
    shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated April 18, 2023, among the Company and the purchasers signatory thereto.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><u>Section 2</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise.</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Exercise

      of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly
    executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the
    Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer
    or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion
    guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has
    purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the
    final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
    Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
    deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
      the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">1</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Exercise

      Price</u>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other
    than the nominal exercise price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such
    pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid exercise price per share of Common Stock under
    this Warrant shall be $0.0001, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Cashless

      Exercise</u>. This Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)]
    by (A), where:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = &#160;&#160;as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the
    applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to
    the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the
    date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such
    Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof
    or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading
    hours&#8221; on such Trading Day;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.5pt; text-align: justify; text-indent: -31.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: -0.5in">(B) = &#160;&#160;&#160;the Exercise Price of this Warrant, as adjusted hereunder; and</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">2</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = &#160;&#160;&#160;the number of Warrant Shares that would be issuable upon exercise of this Warrant in
    accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.5pt; text-align: justify; text-indent: -31.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="background-color: white"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by
      the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the
      Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
      Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open
      Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as
      determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="background-color: white">&#8220;<u>VWAP</u>&#8221; </font>means, for any date, the price determined by
    the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on
    which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
    of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open
    Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined
    by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<font style="background-color: white">.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="background-color: white">If Warrant Shares are issued in such a cashless exercise, the
      parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&#160;&#160;The Company agrees not to take any position contrary to
      this Section 2(c).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">3</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Mechanics
of

      Exercise</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">i.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Delivery
      of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository
    Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
    resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the
    number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) two (2) Trading Days after the delivery to the Company of the
    Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;), in each case subject to the delivery to
    the Company of the aggregate Exercise Price to the Company (if applicable). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
    this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the
    Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of
    Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for
    each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains
    outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the
    date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 04:00 p.m. (New York City time) on the Trading Day immediately prior to the Initial Exercise Date, which may
    be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date
    shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">4</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">ii.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Delivery
      of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a
    new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">iii.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Rescission
      Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">iv.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compensation
      for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the
    provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage
    firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the
    Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the
    Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
    of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the
    Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock
    with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
    indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or
    in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">5</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">v.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No
      Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise,
    the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">vi.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Charges,
      Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
    by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than
    the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse
    it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
    similar functions) required for same-day electronic delivery of the Warrant Shares.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">vii.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Closing
      of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">6</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Holder&#8217;s
Exercise

      Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
    after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution
      Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and
    Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
    (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of
    the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution
    Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
    acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
    therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and
    of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other
    securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or
    confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For
    purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the
    Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or oral
    request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be determined
    after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
    The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
    upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock
    outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
    will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
    otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or
    supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">7</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><u>Section 3</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Certain Adjustments</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Stock
      Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
    payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
    (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case
    the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of
    shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any
    adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
    date in the case of a subdivision, combination or re-classification.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Subsequent

      Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
    record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if
    the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
    date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
    Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
    participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
    time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Pro
      Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
    capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
    (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had
    held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a
    record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the
    extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
    beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not
    result in the Holder exceeding the Beneficial Ownership Limitation).</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">8</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Fundamental

      Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any
    Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase
    offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted
    by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
    reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
    one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group
    of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent
    exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
    regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate
      Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
    in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
    issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of
    the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
    receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing
    all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved
    by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
    substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
    upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking
    into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the
    economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
    Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the
    &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of
    the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor
    Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has
    sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">9</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Calculations</u>.
    All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
    shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">f)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Notice

      to Holder</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">i.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustment
      to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting
    adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">10</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in">ii.<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice
      to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
    (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be
    required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share
    exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the
    Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice
    stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
    such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which
    it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
    exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this
    Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
    entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">11</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><u>Section 4</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Transfer of Warrant</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Transferability</u>.
    This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
    assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
    such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor
    a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
    unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant
    in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>New
      Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
    signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the
    Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares
    issuable pursuant thereto.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Warrant

      Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
    registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><u>Section 5</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Miscellaneous</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>No
      Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
    except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no
    event shall the Company be required to net cash settle an exercise of this Warrant.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">12</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Loss,
      Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the
    Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or
    stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Saturdays,

      Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
    succeeding Business Day.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Authorized

      Shares</u>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 1in">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its
    authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall
    constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure
    that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
    may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
    fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
    including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
    observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as
    set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
    increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
    reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">13</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">Before taking any action which would result in an adjustment in the number of Warrant Shares for which
    this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Jurisdiction</u>.
    All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">f)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Restrictions</u>.
    The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">g)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Nonwaiver

      and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other
    provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
    shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any
    of its rights, powers or remedies hereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">h)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Notices</u>.
    Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Limitation

      of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
    of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">j)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Remedies</u>.
    The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
    compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">k)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Successors

      and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and
    permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">14</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">l)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Amendment</u>.
    This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">m)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Severability</u>.
    Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
    be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">n)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u>Headings</u>.
    The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">********************</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><i>(Signature Page Follows)</i></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">15</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly
    authorized as of the date first above indicated.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt" colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FEMASYS INC.</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt" colspan="2">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="font-size: 10pt; border-bottom: Black 1pt solid">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 50%">&#160;</td>
        <td style="font-size: 10pt; width: 5%">&#160;</td>
        <td style="font-size: 10pt; width: 45%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt">&#160;</td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">16</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>NOTICE OF EXERCISE</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="text-transform: uppercase">To:</font></td>
        <td><font style="text-transform: uppercase"><b>Femasys Inc.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">(1)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160; </font>The undersigned hereby
    elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">(2)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160; </font>Payment shall take the
    form of (check applicable box):</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in">[&#160;&#160; ] in lawful money of the United States; or</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in">[&#160;&#160; ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with
    the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">(3)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160; </font>Please issue said
    Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="text-transform: uppercase">[SIGNATURE OF HOLDER]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 17%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</font></td>
        <td style="width: 83%; font-size: 10pt; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 35%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Signature of Authorized Signatory of Investing Entity</i>:</font></td>
        <td style="font-size: 10pt; width: 65%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 21%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</font></td>
        <td style="font-size: 10pt; width: 79%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 20%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</font></td>
        <td style="font-size: 10pt; width: 80%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</font></td>
        <td style="font-size: 10pt; width: 96%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">&#160;</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"> <b>EXHIBIT B</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-weight: normal">ASSIGNMENT FORM</font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this
      form to exercise the Warrant to purchase shares.)</i></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
        <td style="width: 40%; border-bottom: Black 1pt solid">&#160;</td>
        <td style="width: 10%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</font></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</font></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone Number:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">Dated: _______________ __, ______&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 13%">Holder&#8217;s Signature:</td>
        <td style="border-bottom: Black 1pt solid; width: 27%">&#160;</td>
        <td style="width: 60%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>Holder&#8217;s Address:</td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ny20008824x2_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 4.2</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT A-1</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN
      REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED
      OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
      APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMON STOCK PURCHASE WARRANT</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Femasys Inc.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 70%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</font></td>
        <td style="width: 30%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">Issue Date:______, 2023</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">Initial Exercise Date: _______, 2023</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that,
      for value received, _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the &#8220;<u>Initial
        Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on _____, 20__<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase
      from Femasys Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal
      to the Exercise Price, as defined in Section 2(b).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 1</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Definitions</u>. Capitalized terms
      used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated April 18, 2023, among the Company and the purchasers signatory thereto.&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> <font style="font-size: 9pt;">Insert the date that is the five and
      one-half (5.5) year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">1</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Section 2</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Exercise</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise of Warrant</u>. Exercise of the
      purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail
      (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in
      Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United
      States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
      or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares
      available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is
      delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
      in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any
      Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
        of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise Price</u>. The exercise price per
      share of Common Stock under this Warrant shall be $1.095, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Cashless Exercise</u>. If at the time of
      exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such
      time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) = &#160;&#160;as applicable: (i) the VWAP on the Trading Day
      immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to
      Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the
      VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s
      execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading
      hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to
      Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">2</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B) = the Exercise Price of this Warrant, as adjusted
      hereunder; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X) = the number of Warrant Shares that would be issuable
      upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><u>&#8220;Bid Price</u>&#8221; means, for any
      date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the
      Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume
      weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
      reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
      of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by
      the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<u>VWAP</u>&#8221; </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume
      weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to
      4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
      listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of
      the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding
      and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<font style="background-color: white">.</font></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">3</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If Warrant Shares are issued in such
      a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&#160;&#160;The Company agrees
      not to take any position contrary to this Section 2(c).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Mechanics of Exercise</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Delivery of Warrant Shares Upon Exercise</u>.
      The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or
      Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the
      Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
      the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
      the earlier of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date,
      the &#8220;<u>Warrant Share Delivery Date</u>&#8221;), in each case subject to the delivery to the Company of the aggregate Exercise Price to the Company (if applicable). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate
      purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in
      the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay
      to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
      to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to
      maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of
      Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">4</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Delivery of New Warrants Upon Exercise</u>.
      If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights
      of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160; <u>Rescission Rights</u>. If the Company fails
      to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Compensation for Buy-In on Failure to Timely
        Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i)
      above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases,
      shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by
      which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver
      to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
      number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with
      its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price
      giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to
      the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
      limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">5</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Fractional Shares or Scrip</u>. No
      fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its
      election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Charges, Taxes and Expenses</u>. Issuance of
      Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
      Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this
      Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
      incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
      required for same-day electronic delivery of the Warrant Shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing of Books</u>. The Company will not
      close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">6</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Holder&#8217;s Exercise Limitations</u>. The
      Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set
      forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would
      beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall
      include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the
      remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
      (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&#160;
      Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
      acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
      therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
      and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to
      other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to
      verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
      thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual
      report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon
      the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock
      shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common
      Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this
      Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the
      Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial
      Ownership Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
      implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
      contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">7</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 3</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Certain Adjustments</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Stock Dividends and Splits</u>. If the
      Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock
      (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of
      reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be
      multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock
      outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to
      this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a
      subdivision, combination or re-classification.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Subsequent Rights Offerings</u>. In addition
      to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of
      shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
      number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
      is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>,
      <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right
      to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
      would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">8</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Pro Rata Distributions</u>. During such time
      as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
      limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time
      after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common
      Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such
      Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s
      right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any
      shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
      exceeding the Beneficial Ownership Limitation).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">9</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fundamental Transaction</u>. If, at any time
      while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or
      indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or
      exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50%
      or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
      recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more
      related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons
      whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of
      this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any
      limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate
        Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
      in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
      issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of
      the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
      receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s
      option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the
      Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; <u>provided</u>, <u>however</u>,
      that, if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of
      consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether
      that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <u>provided</u>,
      <u>further</u>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity
      may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg
      determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
      announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of (1) the 30 day volatility, (2) the 100 day volatility or (3) the 365 day volatility, each of clauses
      (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the
      underlying price per share used in such calculation shall be the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of
      the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(e) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable
      contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i)
      five Business Days of the Holder&#8217;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;)
      to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to
      the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a
      written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock
      acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
      capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for
      the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental
      Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction
      Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may
      exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as
      if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of
      (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">10</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Calculations</u>. All calculations under this
      Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
      number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to Holder</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustment to Exercise Price</u>. Whenever
      the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of
      Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">11</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notice to Allow Exercise by Holder</u>. If
      (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the
      granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any
      reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock
      is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by
      email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a
      record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
      redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
      of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the
      failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or
      contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise
      this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">12</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 4</u>. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transfer of Warrant</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transferability</u>. Subject to compliance
      with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are
      transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder
      or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
      assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall
      promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
      surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
      by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>New Warrants</u>. This Warrant may be divided
      or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or
      attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or
      combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Warrant Register</u>. The Company shall
      register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as
      the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transfer Restrictions</u>. If, at the time of
      the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state
      securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder
      or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Representation by the Holder</u>. The Holder,
      by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
      reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">13</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 5</u>. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Miscellaneous</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Rights as Stockholder Until Exercise; No
        Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section
      3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to
      net cash settle an exercise of this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Loss, Theft, Destruction or Mutilation of
        Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of
      loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated,
      the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Saturdays, Sundays, Holidays, etc</u>. If the
      last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Authorized Shares</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company covenants that, during the period the Warrant is
      outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that
      its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
      action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company
      covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
      herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with
      such issue).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">14</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except and to the extent as waived or consented to by the
      Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other
      voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or
      appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
      upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of
      this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
      under this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before taking any action which would result in an adjustment in
      the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies
      having jurisdiction thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Jurisdiction</u>. All questions concerning
      the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Restrictions</u>. The Holder acknowledges
      that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Nonwaiver and Expenses</u>. No course of
      dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the
      Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any
      costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or
      remedies hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notices</u>. Any notice, request or other
      document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">15</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitation of Liability</u>. No provision
      hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
      price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Remedies</u>. The Holder, in addition to
      being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
      incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Successors and Assigns</u>. Subject to
      applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The
      provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Amendment</u>. This Warrant may be modified
      or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severability</u>. Wherever possible, each
      provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
      extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Headings</u>. The headings used in this
      Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Signature Page Follows)</i></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">16</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by
      its officer thereunto duly authorized as of the date first above indicated.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt" colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FEMASYS INC.</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt" colspan="2">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="font-size: 10pt; border-bottom: Black 1pt solid">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 50%">&#160;</td>
        <td style="font-size: 10pt; width: 5%">&#160;</td>
        <td style="font-size: 10pt; width: 45%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt">&#160;</td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">17</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTICE OF EXERCISE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Femasys Inc.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&#160;&#160; The undersigned hereby elects to purchase ________ Warrant Shares of
      the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&#160;&#160; Payment shall take the form of (check applicable box):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[ &#160;&#160;] in lawful money of the United States; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[ &#160;&#160;] if permitted the cancellation of such number of Warrant
      Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&#160;&#160; Please issue said Warrant Shares in the name of the undersigned or
      in such other name as is specified below:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Warrant Shares shall be delivered to the following DWAC Account Number:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)&#160;&#160; <u>Accredited Investor</u>. The undersigned is an &#8220;accredited
      investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE OF HOLDER]</font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 17%; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Name of Investing Entity:</font></td>
        <td style="width: 83%; font-size: 10pt; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 35%"><font style="font: 10pt Times New Roman, Times, Serif"><i>Signature of Authorized Signatory of Investing Entity</i>:</font></td>
        <td style="font-size: 10pt; width: 65%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 21%"><font style="font: 10pt Times New Roman, Times, Serif">Name of Authorized Signatory:</font></td>
        <td style="font-size: 10pt; width: 79%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 20%"><font style="font: 10pt Times New Roman, Times, Serif">Title of Authorized Signatory:</font></td>
        <td style="font-size: 10pt; width: 80%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">Date:</font></td>
        <td style="font-size: 10pt; width: 96%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">&#160;</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>EXHIBIT B</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT FORM</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(To assign the foregoing Warrant, execute this form and supply
        required information. Do not use this form to exercise the Warrant to purchase shares.)</i></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
      thereby are hereby assigned to</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 50%"><font style="font: 10pt Times New Roman, Times, Serif">Name:</font></td>
        <td style="width: 40%; border-bottom: Black 1pt solid">&#160;</td>
        <td style="width: 10%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">(Please Print)</font></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">Address:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">(Please Print)</font></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">Phone Number:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">Email Address:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">Dated: _______________ __, ______&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 13%">Holder&#8217;s Signature:</td>
        <td style="border-bottom: Black 1pt solid; width: 27%">&#160;</td>
        <td style="width: 60%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>Holder&#8217;s Address:</td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ny20008824x2_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><b></b></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><b>Exhibit 4.3</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
      THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES
      ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
      SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Femasys Inc.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 70%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</font></td>
        <td style="width: 30%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">Issue Date:______, 2023</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif">Initial Exercise Date: _______, 2023</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS PLACEMENT AGENT COMMON STOCK
      PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any
      time on or after the date set forth above (the &#8220;<u>Initial Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on April 18, 2028 (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Femasys Inc., a
      Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
      Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain engagement letter, dated as of March 8, 2023, by and between the Company and H.C. Wainwright &amp; Co., LLC.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 1</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Definitions</u>.
      Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated April 18, 2023, among the Company and the purchasers signatory thereto.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">1</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 2</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Exercise</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise of
        Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly
      executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the
      Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire
      transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any
      medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the
      Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date
      on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
      number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.
      The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
        paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise
        Price</u>. The exercise price per share of Common Stock under this Warrant shall be $1.525, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Cashless
        Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be
      exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.5pt; text-align: justify; text-indent: -31.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) =&#160;&#160;&#160; as applicable:
      (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
      and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the
      Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the
      time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close
      of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and
      delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">2</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B) = the Exercise Price of
      this Warrant, as adjusted hereunder; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.5pt; text-align: justify; text-indent: -31.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X) =&#160;&#160;&#160; the number of
      Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.5pt; text-align: justify; text-indent: -31.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><u>&#8220;Bid

        Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the
      nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a
      Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for
      the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair
      market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of
      which shall be paid by the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<u>VWAP</u>&#8221;
    </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the
      daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York
      City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common
      Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid
      price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the
      Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company<font style="background-color: white">.</font></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">3</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
      Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of
      this Warrant.&#160;&#160;The Company agrees not to take any position contrary to this Section 2(c).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Mechanics of
        Exercise</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Delivery of
        Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository
      Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
      resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical
      delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
      Notice of Exercise by the date that is the earlier of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the
      Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;), in each case subject to the delivery to the Company of the aggregate Exercise Price to the Company (if applicable). Upon delivery of the Notice of Exercise, the
      Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of
      the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the
      Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
      Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder
      rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard
      settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">4</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Delivery of
        New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a
      new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Rescission
        Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Compensation
        for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the
      provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage
      firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the
      Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the
      Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
      of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the
      Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock
      with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
      indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or
      in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">5</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No
        Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
      exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Charges,
        Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
      by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other
      than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to
      reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation
      performing similar functions) required for same-day electronic delivery of the Warrant Shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Closing of
        Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">6</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Holder&#8217;s
        Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
      issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution

        Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and
      Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
      (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of
      the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution
      Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
      acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
      therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
      and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to
      other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to
      verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
      thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual
      report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon
      the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock
      shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common
      Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.
      The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
      Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
      Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in
      a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
      changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">7</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 3</u>. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Certain
        Adjustments</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Stock
        Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
      payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
      (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each
      case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
      number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain
      unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
      the effective date in the case of a subdivision, combination or re-classification.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Subsequent
        Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
      record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
      if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
      the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
      Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
      participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
      time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">8</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Pro Rata
        Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than cash) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by
      way of return of capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
      transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if
      the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
      the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>,
      that to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or
      in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
      would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">9</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fundamental
        Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or
      any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
      purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has
      been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any
      reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company,
      directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
      with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;),
      then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
      of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
      consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
      (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
      amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
      value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to
      the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined
      below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
      purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction;
      <u>provided</u>, <u>however</u>, that, if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor
      Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the
      Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the
      Fundamental Transaction; <u>provided</u>, <u>further</u>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common
      stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model
      obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period
      equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of (1) the 30 day volatility, (2) the 100 day volatility or
      (3) the 365 day volatility, each of clauses (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable
      contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated
      Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(e) and (D) a remaining option time equal to the time between the date
      of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such
      other consideration) within the later of (i) five Business Days of the Holder&#8217;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
      is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written
      agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this
      Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its
      parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price
      which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
      of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and
      substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
      each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or
      Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this
      Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled
      to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial
      Exercise Date.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">10</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Calculations</u>.
      All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
      shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to
        Holder</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustment
        to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting
      adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">11</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notice to
        Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
      (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be
      required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share
      exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the
      Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a
      notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
      entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
      date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
      transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice
      provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The
      Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 4</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Transfer
        of Warrant</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transferability</u>.
      Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any
      registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
      duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or
      Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
      assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in
      which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in
      accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">12</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>New Warrants</u>.
      This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the
      Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
      Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
      pursuant thereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Warrant
        Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
      registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transfer
        Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities
      Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing
      such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Representation

        by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view
      to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">13</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Section 5</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Miscellaneous</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Rights as
        Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as
      expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event
      shall the Company be required to net cash settle an exercise of this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Loss, Theft,
        Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the
      Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or
      stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Saturdays,
        Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
      succeeding Business Day.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Authorized
        Shares</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company covenants that, during
      the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The
      Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
      will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
      Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such
      Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
      occurring contemporaneously with such issue).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">14</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except and to the extent as
      waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
      of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
      actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
      the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant
      Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company
      to perform its obligations under this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before taking any action which
      would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
      public regulatory body or bodies having jurisdiction thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Jurisdiction</u>.
      All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Restrictions</u>.
      The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Nonwaiver
        and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other
      provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
      shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
      any of its rights, powers or remedies hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notices</u>.
      Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered to the address for the Holder that appears in the Company&#8217;s Warrant Register.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitation
        of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
      of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">15</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Remedies</u>.
      The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
      compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Successors
        and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and
      permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Amendment</u>.
      This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severability</u>.
      Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
      be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Headings</u>.
      The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Signature Page Follows)</i><br style="clear: both">
    </font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">16</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN WITNESS WHEREOF, the Company has
      caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt" colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FEMASYS INC.</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt" colspan="2">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="font-size: 10pt; border-bottom: Black 1pt solid">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 50%">&#160;</td>
        <td style="font-size: 10pt; width: 5%">&#160;</td>
        <td style="font-size: 10pt; width: 45%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td style="font-size: 10pt">&#160;</td>
        <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">17</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTICE OF EXERCISE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Femasys Inc.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&#160;&#160; The undersigned hereby elects
      to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&#160;&#160; Payment shall take the form of
      (check applicable box):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#160;&#160; ] in lawful money of the
      United States; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#160;&#160; ] if permitted the
      cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
      procedure set forth in subsection 2(c).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&#160;&#160; Please issue said Warrant
      Shares in the name of the undersigned or in such other name as is specified below:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Warrant Shares shall be delivered to the following
      DWAC Account Number:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-left: 1.5in; margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)&#160;&#160; <u>Accredited Investor</u>.
      The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE OF HOLDER]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 17%; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Name of Investing Entity:</font></td>
        <td style="width: 83%; font-size: 10pt; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 35%"><font style="font: 10pt Times New Roman, Times, Serif"><i>Signature of Authorized Signatory of Investing Entity</i>:</font></td>
        <td style="font-size: 10pt; width: 65%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 21%"><font style="font: 10pt Times New Roman, Times, Serif">Name of Authorized Signatory:</font></td>
        <td style="font-size: 10pt; width: 79%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 20%"><font style="font: 10pt Times New Roman, Times, Serif">Title of Authorized Signatory:</font></td>
        <td style="font-size: 10pt; width: 80%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">Date:</font></td>
        <td style="font-size: 10pt; width: 96%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">&#160;</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>EXHIBIT B</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT FORM</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(To assign the foregoing
        Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</i></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR VALUE RECEIVED, the foregoing
      Warrant and all rights evidenced thereby are hereby assigned to</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 50%"><font style="font: 10pt Times New Roman, Times, Serif">Name:</font></td>
        <td style="width: 40%; border-bottom: Black 1pt solid">&#160;</td>
        <td style="width: 10%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">(Please Print)</font></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">Address:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">(Please Print)</font></td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">Phone Number:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">Email Address:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 10.5pt">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">Dated: _______________ __, ______&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 13%">Holder&#8217;s Signature:</td>
        <td style="border-bottom: Black 1pt solid; width: 27%">&#160;</td>
        <td style="width: 60%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>Holder&#8217;s Address:</td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ny20008824x2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 5.1</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr>
        <td style="width: 75%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left; vertical-align: middle"><img alt="" src="ny20008824x2_ex5-1img01.jpg"></td>
        <td style="width: 25%; border-bottom: black 1.5pt solid">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1095 Avenue of the Americas&#160;</p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10036-6797&#160;</p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 212 698 3500 Main&#160;</p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 212 698 3599 Fax&#160;</p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.dechert.com&#160;</p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 20, 2023&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Femasys Inc.&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">3950 Johns Creek Court,&#160;Suite 100&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Suwanee,&#160;Georgia&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Re: <u>Prospectus Supplement to Registration Statement on Form S-3</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Ladies and Gentlemen:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to Femasys Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), in connection with the issuance and sale of (i) 1,318,000
    shares (the &#8220;<u>Shares</u>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (&#8220;<u>Common Stock</u>&#8221;) and (ii) pre-funded warrants (the &#8220;<u>Pre-Funded Warrants</u>&#8221;) to purchase up to 1,878,722 shares (the &#8220;<u>Pre-Funded Warrant Shares</u>&#8221;
    and together with the Shares and the Pre-Funded Warrants, the &#8220;<u>Securities</u>&#8221;) of Common Stock in a registered direct offering, pursuant to the Registration Statement on Form S-3 (File No. 333-266001) (the &#8220;<u>Registration Statement</u>&#8221;), which
    was originally filed with the U.S. Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<u>Act</u>&#8221;), on July 1, 2022, and was declared effective on July 12, 2022, and the related prospectus
    contained therein, dated July 1, 2022 (the &#8220;<u>Base Prospectus</u>&#8221;), and the prospectus supplement, dated April 20, 2023 (the &#8220;<u>Prospectus Supplement</u>,&#8221; and, together with the Base Prospectus, the &#8220;<u>Prospectus</u>&#8221;). All of the Securities are
    to be sold by the Company as described in the Registration Statement and the Prospectus.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion (this &#8220;<u>Opinion</u>&#8221;), we have examined originals or copies (in each case signed, certified or otherwise proven
    to our satisfaction to be genuine) of: (i) the Registration Statement and the Prospectus; (ii) the Company&#8217;s Eleventh Amended and Restated Certificate of Incorporation as filed with the Secretary of State of the State of Delaware on June 22, 2021 (as
    amended to date); (iii) the Company&#8217;s Bylaws, as may be amended and restated from time to time; (iv) the Securities Purchase Agreement dated April 18, 2023 (the &#8220;<u>Purchase Agreement</u>&#8221;) by and between the Company and each of the purchasers party
    thereto (the &#8220;<u>Purchasers</u>&#8221;); (v) the Pre-Funded Warrants; (vi) resolutions of the board of directors of the Company, evidencing corporate action of the Company authorizing the issuance and sale of the Securities; and (vii) a certificate of an
    officer of the Company as to matters of fact material to this Opinion.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as original documents,
    and the conformity to original documents of all documents submitted to us as copies, the legal capacity of natural persons who are signatories to the documents examined by us and the legal power and authority of all persons signing on behalf of parties
    (other than the Company) to all documents.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">&#160;</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have further assumed that the Securities will be issued and sold in the manner stated in the Registration Statement and the Prospectus, and in
    compliance with the applicable provisions of the Act and the rules and regulations of the Commission thereunder and the securities or blue sky laws of various states and the terms and conditions of the Purchase Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our opinions set forth herein are based solely upon the laws of the State of New York and the General Corporation Law of the State of Delaware as
    in effect on the date hereof, and we express no opinion with respect to any other laws, rules or regulations (including, without limitation, the application of the securities or &#8220;Blue Sky&#8221; laws of any state to the offer and/or sale of the Securities).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject to the foregoing, we are of the opinion that, as of the date hereof, (i) the Securities have been duly authorized for
    issuance by the Company, (ii) the Shares, when duly registered on the books of the transfer agent and registrar in the name and on behalf of the purchasers and when issued and sold by the Company and delivered against payment therefor in accordance
    with the terms of the Purchase Agreement, will be validly issued, fully paid and non-assessable, (iii) the Pre-Funded Warrants, when issued and sold by the Company and delivered against payment therefor in accordance with the terms of the Purchase
    Agreement, such Pre-Funded Warrants will be valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, and (iv) the Pre-Funded Warrant Shares, when duly registered on the books of the transfer agent
    and registrar in the name and on behalf of the holders and when issued and delivered by the Company upon exercise and payment of the exercise price of the Pre-Funded Warrants will be validly issued, fully paid and non-assessable.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing of this Opinion as an exhibit to the Company&#8217;s Current Report on Form 8-K filed with the Commission on April 20,
    2023 and as an exhibit to any application under the securities or other laws of any state of the United States which relate to the offer and sale of the Securities. We further consent to the use of our name under the heading &#8220;Legal Matters&#8221; in the
    Prospectus Supplement related to the Registration Statement. In giving such consent, we do not admit hereby that we come within the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission
    thereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Opinion is furnished to you in connection with the closing of the offer and sale of the Securities and is not to be used, circulated, quoted
    or otherwise relied upon for any other purpose, except as expressly provided in the preceding paragraph. This Opinion is furnished as of the date hereof and we disclaim any undertaking to update this Opinion after the date hereof or to advise you of
    any subsequent changes of the facts stated or assumed herein or of any subsequent changes in applicable law.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">

      <tr style="vertical-align: top">
        <td style="width: 60%; padding-left: 10pt">&#160;</td>
        <td style="width: 40%; padding-left: 10pt; font-size: 10pt; text-indent: -10pt">Very truly yours,</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 10pt">&#160;</td>
        <td style="padding-left: 10pt; font-size: 10pt; text-indent: -10pt">/s/ Dechert LLP</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 10pt">&#160;</td>
        <td style="padding-left: 10pt; font-size: 10pt; text-indent: -10pt">Dechert LLP</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <p style="margin: 0"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 3pt">
    <div style="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0"></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>ny20008824x2_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: right; text-indent: -0.5in"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: right; text-indent: -0.5in"><b>Exhibit 10.1</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: center; text-indent: -0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: center; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES PURCHASE
        AGREEMENT</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: center; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Securities Purchase Agreement
      (this &#8220;<u>Agreement</u>&#8221;) is dated as of April 18, 2023, between Femasys Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<u>Purchaser</u>&#8221;
      and collectively the &#8220;<u>Purchasers</u>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS, subject to the terms and
      conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities Act (as defined below) as to the Shares, the Pre-Funded Warrants and Pre-Funded Warrant Shares and (ii) an exemption from the
      registration requirements of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D promulgated thereunder as to the Common Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser,
      severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW, THEREFORE, IN CONSIDERATION
      of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE I.</b><br>
      DEFINITIONS</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Definitions</u>.
      In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Acquiring Person</u>&#8221; shall have
      the meaning ascribed to such term in Section 4.5.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Action</u>&#8221; shall have the
      meaning ascribed to such term in Section 3.1(j).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Affiliate</u>&#8221; means any
      Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Board of Directors</u>&#8221;
      means the board of directors of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Business Day</u>&#8221; means
      any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be
      authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&#160; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental
      authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Closing</u>&#8221; means the
      closing of the purchase and sale of the Securities pursuant to Section 2.1.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">1</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Closing Date</u>&#8221; means
      the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount and (ii) the Company&#8217;s
      obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading Day following the date hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Commission</u>&#8221; means the
      United States Securities and Exchange Commission.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Common Stock</u>&#8221; means
      the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Common Stock Equivalents</u>&#8221;
      means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any
      time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Common Warrants</u>&#8221;
      means, collectively, the common stock purchase warrant delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Common Warrants shall be exercisable immediately upon issuance and have a term of exercise equal to five
      and one-half years, substantially in the form of <u>Exhibit A-2</u> attached hereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Common Warrant Shares</u>&#8221;
      means the shares of Common Stock issuable upon exercise of the Common Warrants.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Company Counsel</u>&#8221; means
      Dechert LLP, with offices located at 1095 Avenue of the Americas, New York, New York 10036.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Disclosure Schedules</u>&#8221;
      means the Disclosure Schedules of the Company delivered concurrently herewith.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Disclosure Time</u>&#8221;
      means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
      date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York
      City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Evaluation Date</u>&#8221; shall
      have the meaning ascribed to such term in Section 3.1(s).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Exchange Act</u>&#8221; means
      the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">2</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Exempt Issuance</u>&#8221; means
      the issuance of (a) shares of Common Stock, restricted stock units or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the
      Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued
      hereunder, warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agent and/or other securities exercisable or exchangeable for or convertible into
      shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
      price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions, partnerships, collaborations, licensing or other
      similar strategic transactions, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
      during the prohibition period in Section 4.11(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in
      a business that is in the opinion of the Company&#8217;s board of directors synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in
      which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>FCPA</u>&#8221; means the
      Foreign Corrupt Practices Act of 1977, as amended.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>FDA</u>&#8221; shall have the
      meaning ascribed to such term in Section 3.1(kk).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>FDCA</u>&#8221; shall have the
      meaning ascribed to such term in Section 3.1(kk).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>GAAP</u>&#8221; shall have the
      meaning ascribed to such term in Section 3.1(h).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Indebtedness</u>&#8221; shall
      have the meaning ascribed to such term in Section 3.1(aa).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Intellectual Property
        Rights</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(p).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Legend Removal Date</u>&#8221;
      shall have the meaning ascribed to such term in Section 4.1(c).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Liens</u>&#8221; means a lien,
      charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Material Adverse Effect</u>&#8221;
      shall have the meaning assigned to such term in Section 3.1(b).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">3</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Material Permits</u>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(n).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Per Share Purchase Price</u>&#8221;
      equals $1.22 (less $0.0001 for each Pre-Funded Warrant), subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement
      and prior to the Closing Date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Person</u>&#8221; means an
      individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Pharmaceutical Product</u>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(jj).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Placement Agent</u>&#8221; means
      H.C. Wainwright &amp; Co., LLC.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Pre-Funded Warrants</u>&#8221;
      means, collectively, the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and will expire when exercised in full,
      substantially in the form of <u>Exhibit A-1</u> attached hereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Pre-Funded Warrant Shares</u>&#8221;
      means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Proceeding</u>&#8221; means an
      action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Prospectus</u>&#8221; means the
      final prospectus filed for the Registration Statement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Prospectus Supplement</u>&#8221;
      means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Purchaser Party</u>&#8221; shall
      have the meaning ascribed to such term in Section 4.8.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Registration Statement</u>&#8221;
      means the effective registration statement filed with the Commission (File No. 333-266001), including all information, documents and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the
      Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares to the Purchasers.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Required Approvals</u>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(e).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Rule 144</u>&#8221; means Rule
      144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as
      such Rule.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">4</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Rule 424</u>&#8221; means Rule
      424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as
      such Rule.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>SEC Reports</u>&#8221; shall
      have the meaning ascribed to such term in Section 3.1(h).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Securities</u>&#8221; means the
      Shares, the Warrants and the Warrant Shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Securities Act</u>&#8221; means
      the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Shares</u>&#8221; means the
      shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Short Sales</u>&#8221; means all
      &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Subscription Amount</u>&#8221;
      means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States
      dollars and in immediately available funds (minus, if applicable, a Purchaser&#8217;s aggregate exercise price of the Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised for cash).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Subsidiary</u>&#8221; means any
      subsidiary of the Company as set forth on <u>Schedule 3.1(a)</u>, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Trading Day</u>&#8221; means a
      day on which the principal Trading Market is open for trading.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Trading Market</u>&#8221; means
      any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
      Exchange (or any successors to any of the foregoing).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Transaction Documents</u>&#8221;
      means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Transfer Agent</u>&#8221; means
      Broadridge Investor Communication Solutions, Inc., the current transfer agent of the Company, with a mailing address of 1155 Long Island Avenue Edgewood, NY 11717, and any successor transfer agent of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Variable Rate Transaction</u>&#8221;
      shall have the meaning ascribed to such term in Section 4.11(b).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">5</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>VWAP</u>&#8221; means, for any
      date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
      date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading
      Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
      Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair
      market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of
      which shall be paid by the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Warrants</u>&#8221; means,
      collectively, the Common Warrants and the Pre-Funded Warrants.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<u>Warrant Shares</u>&#8221; means,
      collectively, the shares of Common Stock issuable upon exercise of the Warrants.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE II.</b><br>
      PURCHASE AND SALE</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing</u>.
      On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $3,900,000.84 of Shares and Warrants.
      Notwithstanding anything herein to the contrary, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser&#8217;s Subscription Amount (together with such Purchaser&#8217;s Affiliates and any Person acting as a group together with
      such Purchaser or any of such Purchaser&#8217;s Affiliates) would cause such Purchaser&#8217;s beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, such Purchaser may elect
      to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant to Section 2.2(a). The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%) of the number of shares of the Common
      Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser. Each Purchaser&#8217;s Subscription Amount as set
      forth on the signature page hereto executed by such Purchaser shall be made available for &#8220;Delivery Versus Payment&#8221; (&#8220;<u>DVP</u>&#8221;) settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares,
      Pre-Funded Warrants and Common Warrants, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions
      set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Company Counsel or such other location (including remotely by electronic transmission) as the Company and the Placement Agent shall mutually agree. Unless otherwise directed
      by the Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#8217; names and addresses and released by the Transfer Agent directly to the account(s) at the
      Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing
      firm) by wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior
      to the Closing (the &#8220;<u>Pre-Settlement Period</u>&#8221;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &#8220;<u>Pre-Settlement Shares</u>&#8221;), such Purchaser
      shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares to
      such Purchaser at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&#8217;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further
      that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any
      Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. </font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">6</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing,
      with respect to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 4:00 p.m. (New York City time) on the Trading Date immediately prior to the Closing Date, which may be delivered at any time after the
      execution of this Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Pre-Funded
      Warrants) for purposes hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Deliveries</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On or prior to the
      Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Agreement
      duly executed by the Company;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a legal opinion
      of Company Counsel, directed to the Placement Agent and the Purchasers, in form and substance reasonably acceptable to the Placement Agent and Purchasers;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;subject to
      Section 2.1, the Company shall have provided each Purchaser with the Company&#8217;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;subject to Section
      2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) Shares equal to such
      Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common Stock issuable upon exercise of such Purchaser&#8217;s Pre-Funded Warrant, if applicable), registered in the name of such Purchaser;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">7</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if applicable, for
      each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the portion of such Purchaser&#8217;s Subscription Amount applicable
      to Pre-Funded Warrant divided by the Per Share Purchase Price minus $0.0001, at an exercise price equal to $0.0001, subject to adjustment therein;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Common Warrant
      registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares and Pre-Funded Warrant Shares, with an exercise price equal to $1.095, subject to adjustment therein;
      and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Prospectus and
      Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On or prior to the
      Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Agreement
      duly executed by such Purchaser; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such Purchaser&#8217;s
      Subscription Amount, which shall be made available for DVP settlement with the Company or its designee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing

        Conditions</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The obligations of
      the Company hereunder in connection with the Closing are subject to the following conditions being met:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the accuracy in
      all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific
      date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) as of such date);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all obligations,
      covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the delivery by
      each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">8</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The respective
      obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the accuracy in
      all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
      (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) as of such date);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all obligations,
      covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the delivery by
      the Company of the items set forth in Section 2.2(a) of this Agreement;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;there shall have
      been no Material Adverse Effect with respect to the Company since the date hereof; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;from the date
      hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
      L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United
      States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial
      market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE III.</b><br>
      REPRESENTATIONS AND WARRANTIES</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Representations
and

        Warranties of the Company</u>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the
      corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Subsidiaries</u>.
      All of the direct and indirect subsidiaries of the Company are set forth on <u>Schedule 3.1(a)</u>. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all
      of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all
      other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">9</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Organization
        and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite
      power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of
      incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the
      nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material
      adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the
      Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;<u>Material Adverse Effect</u>&#8221;)
      and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Authorization;
        Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
      hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all
      necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This
      Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding
      obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
      affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be
      limited by applicable law.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Conflicts</u>.
      The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and
      thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
      (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment,
      anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other
      understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law,
      rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
      or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">10</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Filings,
        Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority
      or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the
      Prospectus Supplement, (iii) application(s) to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv) the filing of Form D with the Commission and (v) such
      filings as are required to be made under applicable state securities laws (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Issuance of
        the Securities; Registration</u>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens
      imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly
      authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which
      became effective on&#160;July 12, 2022, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order
      preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the
      Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any
      amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did
      not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements
      thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue
      statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the
      Registration Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value of securities being sold pursuant to this offering
      and during the twelve (12) calendar months prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">11</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Capitalization</u>.
      The capitalization of the Company as of the date hereof is as set forth on <u>Schedule 3.1(g)</u>, which <u>Schedule 3.1(g)</u> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company
      as of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&#8217;s stock option plans, the
      issuance of shares of Common Stock to employees pursuant to the Company&#8217;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report
      under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale
      of the Securities and as set forth on <u>Schedule 3.1(g)</u>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
      into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or
      any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares
      of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of
      such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no
      contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221;
      plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state
      securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others
      is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the
      Company, between or among any of the Company&#8217;s stockholders.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>SEC Reports;
        Financial Statements</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
      for the two (2) years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
      together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the
      expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any
      untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has
      never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the
      Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<u>GAAP</u>&#8221;),
      except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position
      of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">12</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Material
        Changes; Undisclosed Events, Liabilities or Developments</u>. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on <u>Schedule 3.1(i)</u>, (i) there has been no event, occurrence or
      development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the
      ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its
      method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the
      Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information.
      Except for the issuance of the Securities contemplated by this Agreement or as set forth on <u>Schedule 3.1(i)</u>, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist
      with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this
      representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Litigation</u>.
      Except as set forth on <u>Schedule 3.1(j)</u>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of
      their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;). None of the Actions set forth on <u>Schedule
        3.1(j)</u>, (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a
      Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach
      of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
      has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">13</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Labor
        Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its
      Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and
      its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment
      contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive
      officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations
      relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
      Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Compliance</u>.
      Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
      has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its
      properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule,
      ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and
      labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Environmental
        Laws</u>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
      or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the
      environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions,
      judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii) have received all permits licenses or other approvals required of them
      under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be
      reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">14</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Regulatory
        Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in
      the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings
      relating to the revocation or modification of any Material Permit.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Title to
        Assets</u>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and
      the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the
      Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property
      and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Intellectual
        Property</u>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
      property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the &#8220;<u>Intellectual
        Property Rights</u>&#8221;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate
      or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or
      otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such
      Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
      confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Insurance</u>.
      The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
      including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has been notified that it will not be able to renew its existing insurance coverage
      as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">15</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Transactions
        with Affiliates and Employees</u>. Except as set forth on <u>Schedule 3.1(r)</u>, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is
      presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by,
      providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
      entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for
      services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Sarbanes-Oxley;
        Internal Accounting Controls</u>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof and as of the Closing Date, and
      any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient
      to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP
      and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
      intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the
      Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the
      time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the
      most recently filed periodic report under the Exchange Act (such date, the &#8220;<u>Evaluation Date</u>&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the
      effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the
      Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Certain Fees</u>.
      Except for compensation payable by the Company to the Placement Agent, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent,
      investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons
      for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">16</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Investment
        Company</u>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as
      amended. The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Registration
        Rights</u>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Listing and
        Maintenance Requirements</u>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
      registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice
      from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe
      that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established
      clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Application of
        Takeover Protections</u>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
      agreement) or other similar anti-takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the
      Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Disclosure</u>.
      Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents
      or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the
      foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the
      transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
      therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement
      of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company
      acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">17</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Integrated
        Offering</u>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any
      offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would
      require the registration of the Common Warrants or Common Warrant Shares under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Solvency</u>.
      Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&#8217;s assets
      exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital
      to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
      and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be
      sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of
      cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction
      within one year from the Closing Date. <u>Schedule 3.1(aa)</u> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the
      purposes of this Agreement, &#8220;<u>Indebtedness</u>&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and
      other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for
      deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any
      Subsidiary is in default with respect to any Indebtedness.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">18</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Tax Status</u>.
      Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
      and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to
      be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
      There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Foreign Corrupt
        Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
      contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
      or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any
      material respect any provision of FCPA.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Accountants</u>.
      The Company&#8217;s independent registered public accounting firm is set forth on <u>Schedule 3.1(dd)</u> of the Disclosure Schedules. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required
      by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ended December 31, 2022. </font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Acknowledgment

        Regarding Purchasers&#8217; Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions
      contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and
      any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Securities. The
      Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and
      its representatives.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">19</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Acknowledgment
Regarding

        Purchaser&#8217;s Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has
      been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Securities for
      any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions, before or after the closing of this or future private placement
      transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which any such Purchaser is a party, directly or indirectly, presently may have
      a &#8220;short&#8221; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction. </font>The Company further understands and acknowledges
    that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to
    Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&#8217; equity interests in the Company at and after the time that the hedging activities are being conducted.&#160; The Company
    acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      &#160;&#160; &#160;&#160;&#160;&#160;&#160; <u>Regulation
        M Compliance</u>.&#160; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
      Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for
      soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      <u>FDA</u>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;<u>FDCA</u>&#8221;) that is manufactured,
      packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;<u>Pharmaceutical Product</u>&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed,
      sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good
      manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect.
      There is no pending, completed or, to the Company&#8217;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its
      Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or
      approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure
      of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins
      production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
      rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all
      material respects in accordance with all applicable laws, rules and regulations of the FDA.&#160; The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to
      be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">20</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      <u>Stock Option Plans</u>. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan and (ii) with an exercise price at least equal to the fair
      market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock option plan has been backdated. The Company has not knowingly granted, and
      there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the
      Company or its Subsidiaries or their financial results or prospects.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      <u>Cybersecurity</u>.&#160; (i)(x) There has been no security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its
      respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of,
      and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable
      laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the
      protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&#160;the Company and the Subsidiaries have implemented and
      maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have
      implemented backup and disaster recovery technology consistent with industry standards and practices.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      <u>Office of Foreign Assets Control</u>. Neither the Company nor any Subsidiary nor, to the Company&#8217;s knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions
      administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;<u>OFAC</u>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>U.S.

        Real Property Holding Corporation</u>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon
      Purchaser&#8217;s request.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">21</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Bank

        Holding Company Act</u>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;<u>BHCA</u>&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the
      &#8220;<u>Federal Reserve</u>&#8221;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or
      more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of
      a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Money

        Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
      1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<u>Money Laundering Laws</u>&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or
      any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      <u>Private Placement</u>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Common Warrants or the Common Warrant
      Shares by the Company to the Purchasers as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No

        General Solicitation</u>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Common Warrants or Common Warrant Shares by any form of general solicitation or general advertising. The Company has offered
      the Common Warrants and Common Warrant Shares for sale only to the Purchasers and certain other &#8220;accredited investors&#8221; within the meaning of Rule 501 under the Securities Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No

        Disqualification Events</u>. With respect to the Common Warrants and Common Warrant Shares to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any
      director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
      (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &#8220;<u>Issuer Covered Person</u>&#8221;) is subject to any of the &#8220;Bad Actor&#8221; disqualifications described in Rule
      506(d)(1)(i) to (viii) under the Securities Act (a &#8220;<u>Disqualification Event</u>&#8221;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is
      subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Other

        Covered Persons</u>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with
      the sale of any Securities.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">22</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice

        of Disqualification Events</u>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the
      passage of time, reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Representations

        and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which
      case they shall be accurate as of such date):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Organization;
        Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership,
      limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the
      Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on
      the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation
      of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
      enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
      applicable law.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Understandings
        or Arrangements</u>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
      representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
      hereunder in the ordinary course of its business. Such Purchaser understands that the Common Warrants and the Common Warrant Shares are &#8220;restricted securities&#8221; and have not been registered under the Securities Act or any applicable state securities
      law and is acquiring such Securities as principal for his, her or its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law,
      has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding
      the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&#8217;s right to sell such Securities pursuant to a registration statement or
      otherwise in compliance with applicable federal and state securities laws).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">23</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Purchaser
        Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be an &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3),
      (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Experience of
        Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective
      investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such
      investment.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Access to
        Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as
      it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about
      the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company
      possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&#160; Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of
      the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&#160; Neither the Placement Agent nor any Affiliate has made or makes any representation
      as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&#160; In connection with the issuance
      of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Certain
        Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly
      executed any purchases or sales, including Short Sales,&#160;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing
      the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby
      separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the
      representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this
      Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made
      to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any
      actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">24</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>General
        Solicitation</u>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television
      or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21pt; text-align: justify; text-indent: 51pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acknowledges and agrees
      that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any
      other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing
      contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE IV.</b><br>
      OTHER AGREEMENTS OF THE PARTIES</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Removal of Legends</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Common Warrants
      and Common Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Common Warrants and Common Warrant Shares other than pursuant to an effective registration statement or Rule
      144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and
      reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Common Warrants under the Securities
      Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Purchasers agree
      to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Common Warrants and Common Warrant Shares in the following form:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER THIS SECURITY NOR THE SECURITIES INTO
      WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES
      ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
      SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
      LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">25</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company
      acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Common Warrants and Common Warrant Shares to a financial
      institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Common Warrants and Common Warrant Shares to the
      pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall
      be required of such pledge. At the appropriate Purchaser&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Common Warrants and Common Warrant Shares may reasonably request in connection
      with a pledge or transfer of Common Warrants and Common Warrant Shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certificates

      evidencing the Common Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii)
      following any sale of such Common Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Common Warrant Shares), or (iii) if such Common Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Common
      Warrants), or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
      opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all or any portion of a Common Warrant is exercised at a time
      when there is an effective registration statement to cover the resale of the Common Warrant Shares, or if such Common Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the Common Warrant Shares) or if such legend is not
      otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Common Warrant Shares shall be issued free of all legends. The Company
      agrees that following such time as such legend is no longer required under this Section 4.1(c), the Company will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as
      defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Common Warrant Shares, as applicable, issued with a restrictive legend (such date, the &#8220;<u>Legend Removal Date</u>&#8221;), deliver or
      cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the
      restrictions on transfer set forth in this Section 4. Common Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&#8217;s prime broker with the Depository
      Trust Company System as directed by such Purchaser. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common
      Stock as in effect on the date of delivery of a certificate representing Common Warrant Shares issued with a restrictive legend.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">26</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In

      addition to such Purchaser&#8217;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of Common Warrant Shares (based on the VWAP of the Common Stock on the date
      such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue)
      for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate
      representing the Securities so delivered to the Company by such Purchaser that is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of
      Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock,
      that such Purchaser anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of such Purchaser&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the
      shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<b><u>Buy-In Price</u></b>&#8221;) over the product of (A) such number of Common Warrant Shares that the Company was required to deliver to
      such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser to the Company of the applicable Common
      Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this Section 4.1(d).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The

      Shares shall be issued free of legends. If all or any portion of a Pre-Funded Warrant is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Pre-Funded Warrant Shares or if the Pre-Funded
      Warrant is exercised via cashless exercise, the Pre-Funded Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration
      statement registering the sale or resale of the Pre-Funded Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Pre-Funded Warrant Shares, the Company shall immediately notify the holders of the Pre-Funded
      Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of the Pre-Funded Warrant Shares (it
      being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Pre-Funded Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use
      commercially reasonable efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Pre-Funded Warrant Shares effective during the term of the Pre-Funded Warrants.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">27</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Furnishing
of

        Information</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Until

      the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be
      filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At

      any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the Common Warrant Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in
      compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer
      described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#8220;<u>Public Information Failure</u>&#8221;) then, in addition to such Purchaser&#8217;s other available remedies,
      the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Common Warrant Shares, an amount in cash equal to one percent (1.0%) of the
      aggregate Exercise Price of such Purchaser&#8217;s Common Warrants on the day of a Public Information Failure and on every thirtieth (30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day (pro rated for periods totaling
      less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer required&#160; for the Purchasers to transfer the Common Warrant Shares pursuant to
      Rule 144.&#160; The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b) are referred to herein as &#8220;<u>Public Information Failure Payments</u>.&#8221;&#160; Public Information Failure Payments shall be paid on the earlier of (i) the last
      day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the third (3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>) Business Day after the event or failure giving rise
      to the Public Information Failure Payments is cured.&#160; In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated
      for partial months) until paid in full. Nothing herein shall limit such Purchaser&#8217;s right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity
      including, without limitation, a decree of specific performance and/or injunctive relief.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Integration</u>.
      The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that
      would require the registration under the Securities Act of the sale of the Common Warrants or Common Warrant Shares or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market
      such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">28</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Securities

        Laws Disclosure; Publicity</u>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction
      Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material,
      non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, in connection
      with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
      written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of
      their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The
      Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any
      such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
      be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company
      shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by
      federal securities law in connection with (i) filing any registration statement of the Company providing for the resale by the Purchasers of the Common Warrant Shares issued and issuable upon exercise of the Common Warrants and (ii) the filing of
      final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this
      clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Shareholder
        Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;<u>Acquiring Person</u>&#8221; under any control share acquisition, business combination, poison pill
      (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by
      virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">29</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Non-Public

        Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any
      other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall
      have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in
      effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser
      without such Purchaser&#8217;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or
      agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to
      trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material,
      non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms
      that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Use
        of Proceeds</u>. Except as set forth on <u>Schedule 4.7</u> attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of
      any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any
      outstanding litigation or (d) in violation of FCPA or OFAC regulations.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">30</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Indemnification

        of Purchasers</u>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally
      equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the
      directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons
      (each, a &#8220;<u>Purchaser Party</u>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and
      costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction
      Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the
      transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&#8217;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
      such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence
      or willful misconduct) or (c) in connection with any registration statement of the Company providing for the resale by the Purchasers of the Common Warrant Shares issued and issuable upon exercise of the Common Warrants, the Company will indemnify
      each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#8217; fees) and expenses, as incurred, arising out of or
      relating to (i) any untrue or alleged untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of
      or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were
      made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by such Purchaser Party expressly for
      use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought against any
      Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own
      choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
      such Purchaser Party except to the extent that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (z) in
      such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees
      and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be
      unreasonably withheld or delayed; or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such
      Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills
      are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to
      law.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Reservation

        of Common Stock</u>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the
      Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">31</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Listing

        of Common Stock</u>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company
      shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the
      Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on
      such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting,
      filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation,
      including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Subsequent
        Equity Sales</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; From the date
      hereof until forty-five (45) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock
      Equivalents or (ii) file any registration statement or any amendment or supplement thereto, in each case other than the Prospectus Supplement or the filing of a registration statement or any amendment thereto with respect to the Common Warrant
      Shares.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; From the date
      hereof until the one (1) year anniversary of the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
      (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;<u>Variable Rate Transaction</u>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
      exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the
      shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity
      security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not
      limited to, an equity line of credit or an &#8220;at-the-market&#8221; facility, whereby the Company may issue securities at a future determined price; <u>provided</u>, <u>however</u>, that, after six (6) months following the Closing Date, the issuance of
      shares of Common Stock in an &#8220;at-the-market&#8221; facility with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such
      issuance, which remedy shall be in addition to any right to collect damages.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">32</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding
      the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Equal Treatment
        of Purchasers</u>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also
      offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
      the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Certain
        Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or
      sales, including Short Sales of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to
      the initial press release as described in Section 4.4.<font style="color: windowtext">&#160; </font>Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are
      publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure
      Schedules (other than as disclosed to its legal and other representatives).&#160; N<font style="color: windowtext">otwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges
        and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first
        publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws
        from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to
        trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including, without limitation, the Placement Agent, after the issuance of the initial
        press release as described in Section 4.4.&#160; </font>Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the
      portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by
      the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: windowtext"><u>Exercise Procedures</u>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other
        information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of
        guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods
        set forth in the Transaction Documents.</font></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">33</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: windowtext"><u>Form D; Blue Sky Filings</u>. If applicable, the Company agrees to timely file a Form D with respect to the </font>Common Warrants <font style="color: windowtext">and </font>Common Warrant Shares <font style="color: windowtext">as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to
        qualify the </font>Common Warrants and Common Warrant Shares <font style="color: windowtext">for, sale to the Purchasers at the Closing under applicable securities or &#8220;Blue Sky&#8221; laws of the states of the United States, and shall provide evidence
        of such actions promptly upon request of any Purchaser.</font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE V.</b><br>
      MISCELLANEOUS</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination</u>.&#160;

      This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
      Closing has not been consummated on or before the fifth (5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Trading Day following the date hereof; <u>provided</u>, <u>however</u>, that no such termination will
      affect the right of any party to sue for any breach by any other party (or parties).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fees

        and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
      incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter
      delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Entire

        Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and
      supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notices</u>.
      Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
      delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or
      communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice
      is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">34</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Amendments;

        Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares
      and Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided
      that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any
      default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor
      shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any
      Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each
      Purchaser and holder of Securities and the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Headings</u>.
      The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Successors

        and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written
      consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be
      bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &#8220;Purchasers.&#8221;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No
        Third-Party Beneficiaries</u>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the Company in Section 3.1, the representations and warranties of the Purchasers in Section 3.2 and the covenants of
      the Company in Section 4. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as
      otherwise set forth in Section 4.8 and this Section 5.8.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">35</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Governing

        Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
      to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether
      brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby
      irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
      hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
      jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or
      Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good
      and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any
      provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and
      other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Survival</u>.
      The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Execution</u>.
      This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
      it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by electronic mail, or otherwise by electronic transmission (including any electronic signature complying with the U.S. federal
      ESIGN Act of 2000, e.g.,www.docusign.com) evidencing an intent to sign this Agreement, such electronic mail or other electronic transmission shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
      executed) with the same force and effect as if such signature page were an original. Execution and delivery of this Agreement by electronic mail or other electronic transmission is legal, valid and binding for all purposes.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Severability</u>.
      If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
      remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same
      result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without
      including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">36</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Rescission and
        Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a
      Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any
      relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; <u>provided</u>, <u>however</u>, that in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to
      return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#8217;s right to
      acquire such shares pursuant to such Purchaser&#8217;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Replacement of
        Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of
      mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument
      under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Remedies</u>.
      In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree
      that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such
      obligation the defense that a remedy at law would be adequate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Payment Set
        Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
      or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any
      other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be
      satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Independent
        Nature of Purchasers&#8217; Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
      performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed
      to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the
      transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
      Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the
      Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through the legal counsel of the Placement Agent. The legal counsel of the Placement Agent
      does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or
      requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
      the Purchasers collectively and not between and among the Purchasers.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">37</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Liquidated
        Damages</u>. The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and
      other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Saturdays,
Sundays,

        Holidays, etc.</u> If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
      Business Day.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Construction</u>.
      The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
      the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to
      adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><u>WAIVER

          OF JURY TRIAL</u>. <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY,
          UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </u></b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Signature Pages Follow)</i></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">38</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN WITNESS WHEREOF, the parties
      hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FEMASYS INC.</b></font></td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Address for Notice:</u></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2">&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="width: 35%; border-bottom: Black 1pt solid">&#160;</td>
        <td style="width: 10%">&#160;</td>
        <td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to (which shall not
      constitute notice):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">39</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER SIGNATURE PAGES TO <font style="text-transform: uppercase">FEMY</font> SECURITIES PURCHASE AGREEMENT]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN WITNESS WHEREOF, the
      undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="width: 14%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Purchaser:</font></td>
        <td style="width: 86%; border-bottom: Black 1pt solid">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 33%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Signature of Authorized Signatory of Purchaser</i>:</font></td>
        <td style="border-bottom: Black 1pt solid; width: 67%">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 22%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</font></td>
        <td style="border-bottom: Black 1pt solid; width: 78%">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 20%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</font></td>
        <td style="border-bottom: Black 1pt solid; width: 80%">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">

      <tr style="vertical-align: top">
        <td style="font-size: 10pt; width: 27%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address of Authorized Signatory:</font></td>
        <td style="border-bottom: Black 1pt solid; width: 73%">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice to Purchaser:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Delivery of Warrants to Purchaser (if not same as address for
      notice):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Amount: $_________________</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares: _________________</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants: _______________ Beneficial Ownership Blocker &#9744; 4.99%
      or &#9744; 9.99%</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Warrants: _____________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744;
      9.99%</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN Number: _______________________</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; Notwithstanding anything contained in this Agreement
      to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to
      the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur by the second (2nd) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this
      Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall
      instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">40</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE PAGES CONTINUE]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <p style="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0"></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>ny20008824x2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 99.1</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under
        Nasdaq Rules</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATLANTA, April 19, 2023 -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet
      women&#8217;s needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has entered into a definitive agreement for the issuance and sale of an
      aggregate of 3,196,722 of its shares of common stock (or common stock equivalents) at a purchase price of $1.22 per share (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private
      placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary
      closing conditions.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants will have an exercise price $1.095 per share, will become exercisable
      immediately upon issuance and have a term of five and one-half years from the date of issuance.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross proceeds to the Company from the offering are expected to be approximately $3.9
      million, before deducting the placement agent&#8217;s fees and other offering expenses payable by Femasys. Femasys currently intends to use the net proceeds from the offering for working capital and general corporate purposes.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares of common stock (or common stock equivalents) offered in the registered direct
      offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of common stock underlying such unregistered warrants) are being offered and sold by the Company pursuant to a &#8220;shelf&#8221; registration statement
      on Form S-3 (Registration No. 333-266001), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on July 1, 2022 and declared effective by the SEC on July 12, 2022. The offering of the shares of common stock
      (or common stock equivalents) to be issued in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus
      relating to the registered direct offering will be filed with the SEC and will be available on the SEC&#8217;s website located at&#160;<u>http://www.sec.gov</u>. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be
      obtained by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at <u>placements@hcwco.com</u>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The offer and sale of the unregistered warrants described above are being made in a
      transaction not involving a public offering and have not been registered under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and/or Rule 506(b) of Regulation D promulgated thereunder and, along with the shares of
      common stock underlying such unregistered warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be reoffered or resold in
      the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">&#160;</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This press release shall not constitute an offer to sell or a solicitation of an offer to
      buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or
      jurisdiction.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>About Femasys</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Femasys Inc. is a biomedical company aiming to meet women&#8217;s needs worldwide by developing a
      suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc&#174; permanent birth control and FemaSeed&#174; localized directional insemination for
      infertility. The Company&#8217;s products currently marketed in the United States, include FemVue&#174; for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath&#8482;, an intrauterine catheter for selective evaluation of the
      fallopian tubes, and FemCerv&#174;, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward-Looking Statements</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This press release contains forward-looking statements that are subject to substantial risks
      and uncertainties. Forward-looking statements can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;pending,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;hope,&#8221; or &#8220;continue&#8221; or the negative of these terms or
      other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond
      our control, difficult to predict and could cause actual results to differ materially from what we expect, and include, among others, statements regarding the completion of the registered direct offering, the satisfaction of customary closing
      conditions related to the registered direct offering and the anticipated use of proceeds therefrom. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause
      actual results to differ include, among others: market and other conditions, our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our
      clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products,
      technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022 and other reports as filed
      with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div class="BRPFPageNumberArea" style="TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">&#160;</font></div>
    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contacts:</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investors</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chuck Padala&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci Advisors, LLC&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1-917-741-7792&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>chuck@lifesciadvisors.com</u></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Femasys Inc.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Contact:&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>IR@femasys.com</u></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media Contact:&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Media@femasys.com</u></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT" style="margin-top: 3pt; margin-bottom: 0pt">
    <div style="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>femy-20230418.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<xs:schema targetNamespace="http://femasys.com/20230418" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:femy="http://femasys.com/20230418" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="femy-20230418_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="femy-20230418_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://femasys.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>femy-20230418_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:label xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="dei_EntityExTransitionPeriod_lbl">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:title="label: EntityExTransitionPeriod to dei_EntityExTransitionPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>femy-20230418_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://femasys.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="femy-20230418.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://femasys.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityExTransitionPeriod" xlink:title="presentation: CoverAbstract to EntityExTransitionPeriod" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ny20008824x2_ex5-1img01.jpg
<TEXT>
begin 644 ny20008824x2_ex5-1img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ .0"5 P$1  (1 0,1 ?_$ ((   $$ P$
M       "!08' 0,$" $!                     !   0(% @,#!P@&"P$
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M_@EQ_='("(^&/\GK/^G](@+34@$S/9 4&ZCX1XLV13G:B\VA8J1V*(5OF?\
M;$!ON5-5]6NIMTL-54.LX3BH;16TS#BFQ5U;TRD.*002E*4'2 ?,H\.F /VA
M;F.T/P.]4B"JWW"B6MMP+2)C=(^W,CM@.CHMU"K+UT^JZB^K"KMCCU1071P\
M5KI@%!1_1('I@(?T]P]KJ\Y69WFQ=KK0_4.,X_9BXM%,W3L++846TE(4HJ29
MS@'C/>A%NM]'\?Z;,&QY/;REUA%(M2&WPC7EK;GL,^S2 8?$I<+R>F&+W"YT
M?(NW>6':ND'M!+^U)4C];2 EN-=%K9>VTY#U#2J^9'7 N/,5"UJIJ7?KR6F)
M\L;.'" BU18:3IAUQQFEQG?26+)PXQ6VQ*U%G>=$*2DD[9*D8!]ZIW&]9=G]
MNZ86NL=M] XWW[(:JG64.=V1JEH*3JD+5(& =JCPX]*'[6:!NS)IZ@IFU7MK
M<%2A:>#G,W;ISUU@&[H;D=\I+S?^GM_J55=;CRTKH*EPS6Y3*TU)X[?9@*DZ
M98U>,US7*<8-2_28RS<E5EZ6PM3:WC-:&:<J21HJ:SZH"ZW?#9T;;IW"FP)"
MDMF1Y[\]!V^W 5=T Z-].LGMF3.WNTIJW*"]U5'2J+CJ"EEM+90CV%)X;C >
M@/Y<X?\ @K\&=Q_\YMV=RYCG#G]X]_=O^]]KC (ZJ?EAF'\$N/[HY 1#PQD#
MH]9O.5CZ("U%+ \XX^8=NL!0-E>&3>*:OKZ7VZ3';8:=UWBD.J6!('SA?S0$
M:Z587D619/G2;=EE?C[M)<D]YIZ)03O#G,Y:U_JF4!9!Z.9VDC_Z5>R3Y7(#
M12]*W,(P',FVKK47:KO#;E4\Z_+=S2D;C[($Y]L [>'!VF7T7QPL'V4H?2J7
MV^\N[OG@+,'9Y9:" I#Q4)2<:L&X32;HW,<-"4S@+P"2-"8"C^LGYT=,@3H:
MJ1_7@(U78U>KYXD,@H:._P!7C]4JWH=;J:,[7%MA21LF>S6<!.3T;SN7YE7S
MT<R [\ Z0/XOE]9E5;D59>ZVMI32.JJ]IF.8A85,"<QLD/28"+^&9L?%.H#@
M]XW9()/$@<W0_+ 7C5?\9[_(KZ# 4IX6C_T^8^?)*W_0U 7CV0$9ZH(6[TUR
MUII)6ZY9K@AMM()4I1I7   .))@//723KLQAF#4./5V,W9^II K<ZTP0DSEH
M)B<!);AUMZD9HRJSX%B-=1/5*2TNZUK90AA*M"H+/L CSGT0%B='^E[.!V!Y
MMYT5E[N3@?NM;VK<$Y)!/U4[C 0C+;!EO3KJ74YWC5L=N]@O381?[=2)W.H6
MCW74H&IT[1P]< Z5GB(H:FA6SC^/7>NO;@VLT9HWD[7#PYBE("?9],!(NE>-
MYFQCU<_FM<Y57.]NK?>H5K*T4K3B0E+*![HD.,! + YE71B\7*U5%HJ[O@M;
M4*J[?74#:WETQ<U4A:4 D 0#G?NKV19?2+L?3RR7#OE8-CEXJ*=RGIV$JXJW
M.!.H@&CK=B]UMG3;$+,JHJ+S645:R*FL(4ZM:D[=ZB=3*?"<!Z%F#P@*4ZO4
M=4_UBZ;OLLN+98J277D(44)]OZR@)#UP&_J[A>54F5VKJ5AU.:R[6H%FOH&]
M5U%*L;%!*?K%*2=(#+7B-LB:38_CUX;O 29VWN;Y67/LA6S;J?/ ./2BDZBW
M.]W3,,L6];Z6X(2S:\>4HA#385NYBT3D%]GEXP#'X;J.KIJ[/#4,K9#MU"FM
MZ2G<!S-4SXC6 NE\;VG$IE-:5)'R?WP'FOI=G8Z85V56+*+3<67*J[U%?25#
M-*ZZVMIT) D4)5/W8"Z_YB6/\!G,^14_"O>Y7=W>?]_R9\G;S/>\W#6 EBPH
MH( UEZOG@$I9;($T >H" R$)!]G3YH#(GVCTSXP H$B7$>K^N 3L2-4I$S]:
M4C *,Y:<)?/], 2F/: ,O+K 8" -$I"03Q  @,+0#]7=K,3D?I@%#3LT)D?+
MK )*!HHI!4G4B0X\=(!0 .A'#RP">4G<5;1/MT$SZQ + E_; ,^-7U%[M::Y
MMHL)6XZT4&4_V2RB<TSXR@,6K($7"[W>VI;+9M+C3:UJ.BN8C?. :\@R:ZTV
M0_"+9:TURVJ--<\XXXA VK<<0$I*B-?V)@%?C6A_ WXH[LKD\.Z23NYO.Y'+
MX[/O=-TY2U@)= )D8 D8 D8 D8 D8 D8 D8 D8 D8 D8 D8 D8 D8 D8"#8,
M<EM5(BS5U@J6VQ4/J->'Z,M<MQQ2TJVI?4[K/[$!BA;R6T9;?GTV&IKZ*Z/L
M.4]8P_2! 2AH(.Y#KS;FA\B3 *O&#M7O.1<[E1ARVBV,TZ%%:='DOO+6A20=
MVB5IUE* E/P6U_"/A7=D?#]G+[O+V-OH], XP! $ 0! $ 0! $ 0! $ 0! $
2!CZQ] @#R0 .'RP!]7U0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549779473456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 18,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FEMASYS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001339005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3713499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3950 Johns Creek Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Suwanee<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-3910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FEMY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>ny20008824x2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="femy-20230418.xsd" xlink:type="simple"/>
    <context id="c20230418to20230418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001339005</identifier>
        </entity>
        <period>
            <startDate>2023-04-18</startDate>
            <endDate>2023-04-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230418to20230418"
      id="Fact_52abcf78c0504798930b00bc8d1737ac">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="c20230418to20230418"
      id="Fact_3d14ca5a433c404c86a606c38ab05c4d">FEMASYS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="c20230418to20230418"
      id="Fact_24af1c380ae44bd0856779dd5e61a378">0001339005</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20230418to20230418"
      id="Fact_061fc63a2fef4a43a00dda4f8cec9231">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20230418to20230418"
      id="Fact_3c647021cade46af8a79964193c2eb21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230418to20230418"
      id="Fact_15af6706b1594690814dc3201ef1cf64">2023-04-18</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230418to20230418"
      id="Fact_77736e12ac2c4de7b53e40e220e71e11">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230418to20230418"
      id="Fact_2d7f8bf357f049b7acd1bf9261b5d147">001-40492</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230418to20230418"
      id="Fact_18b3fe7b9a37491fa70112503787a1c7">11-3713499</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230418to20230418"
      id="Fact_884a4941557942a1ba3470453ce9fe1d">3950 Johns Creek Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20230418to20230418"
      id="Fact_bfb239de31db4307b75e319b7487cab5">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20230418to20230418"
      id="Fact_d8932f83426e4044abb90fb6d0f5796c">Suwanee</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230418to20230418"
      id="Fact_9f7ae5473ef947c7bb889ff35ea80454">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230418to20230418"
      id="Fact_2f4ecaa164a9494093fb4c947cb51897">30024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230418to20230418"
      id="Fact_236f184e53ed45ffa1c861107f1ac8da">770</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230418to20230418"
      id="Fact_782c19ef3b9a4a8e92c1f4ddecb12c55">500-3910</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20230418to20230418"
      id="Fact_717e92c7e24548a1b6bd02a0b748cef2">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230418to20230418"
      id="Fact_05e8ae921f9b489c8c71c357582db30a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230418to20230418"
      id="Fact_2a9bc928c84f42c8b710efed90971493">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230418to20230418"
      id="Fact_4976e1d201b243cd90f0487fbc02ba50">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20230418to20230418"
      id="Fact_02ee142125064a74ba08b3ca4f99006d">Common Stock, par value $0.001 per value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230418to20230418"
      id="Fact_8bc4942cc66946dd932bf5524f8ec334">FEMY</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230418to20230418"
      id="Fact_ea8ee2027cd747b8b5a7cca646c3f8c9">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="c20230418to20230418"
      id="Fact_4b6e330c8784449ea978dbf6f32f1a15">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #A-E%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  X39160DS#5NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$["#B;U96.G%@8K;.QF;+4UBQUC:R1]^R59FS*V!]C1TN]/
MGT"MB=+T"9]3'S&1PWPW^BYD:>*&G8BB!,CFA%[G<DJ$J7GHD]<T/=,1HC8?
M^HA0<7X/'DE;31IF8!%7(E.M-=(DU-2G"]Z:%1\_4[? K 'LT&.@#*(4P-0\
M,9['KH4;8(81)I^_"VA7XE+]$[MT@%V28W9K:AB&<JB7W+2#@+?=]F59MW A
MDPX&IU_923I'W+#KY-?ZX7'_Q%3%J[K@35'QO:AE(V13O\^N/_QNPKZW[N#^
ML?%54+7PZR[4%U!+ P04    "  X3916F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #A-E%9MYM)"? 0  ,81   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC9AA<^(V$(;_BL;M=-J9))9L""$%9CA"KO0N.1K3WEP[_2!L 9K8EBO+@?S[
MK@RQ:6K6? '+EEX_6JW?M3S8*OV<;X0P9)?$:3YT-L9DMZZ;AQN1\/Q*92*%
M*RNE$VZ@J==NGFG!HW)0$KL>I==NPF7JC ;EN;D>#51A8IF*N29YD21<OWX0
ML=H.'>:\G7B2ZXVQ)]S1(.-K$0CS>S;7T'(KE4@F(LVE2HD6JZ$S9K<?O&L[
MH.SQAQ3;_.B8V*DLE7JVC5DT=*@E$K$(C97@\/<B)B*.K1)P_',0=:I[VH''
MQV_J]^7D83)+GHN)BK_*R&R&SHU#(K'B16R>U/87<9A0U^J%*L[+7[+=]^UT
M'!(6N5')83 0)#+=__/=(1#' ]B) =YA@%=R[V]44MYQPT<#K;9$V]Z@9@_*
MJ9:C 4ZF=E4"H^&JA'%F=*?" H)L"$\C,DV--*]DENY7&Z(V< W<Q'9UPX/@
MA[V@=T)PG.DKPFXNB$<]_[_#76"K +T*T"OU_!-Z$_4B-/EKO,R-AB7\NXEH
MK]!I5K!Y?9MG/!1#!Q(W%_I%.*,?OF/7]&>$SZ_X?$R]#N#B-1--</CPF\M/
M"$2G@NB@*F,@B$J*^YBOFRCP\2L>YP+AZ%8<W?.",1=:*IM0$8&T;(P+KE2E
M45L>75=HUZC@(;?O92S(8Y$LA6Z"PC4H99<=VNE["$^OXNF=P_,DUM)F-L3L
MD2>-@<)U[J</X^!;0&:/$X3JIJ*Z.8=J FNH>0Q.$(D=^21>F[AP)0K!\OT^
MI5T$JU]A]<_!FJ6ATIG2I35=D,! :A&ER405P O8*FJ,("Y^-T4(&:V-E)[#
MN. [,HL@?G(EPQ(42;<62<8N_1[S._T^1GAD]>P<PG$4@0WF%V\'Y#/T(U_2
MQM"U2/K]+B6_JDV:DXD6XMDNA388;>W[#+5MG':Q58VTN&102$@81BD&6!L_
MPZW[/>#$MB ;%VK;7#=QN:#8\E1@+LSJ<L!P/W^/5CTI<ZU>9!HV+S6N^7&,
MH=45@N'&_AYMKG(#3O.GS$X^OBV*/J5>!V.K2P3#_;U<P3&\W)Y&P05Z/32U
MZMK <%/_K$*(R7RC4JQ8M8AT*;WT^PPEJNL"P^U\(0T43K4BS/MQ^1,)1%AH
MB%8C%JXT44D"IA@8%3Y?D(QK\L+C0I#OZ164#)*)PPD,NZX;#/?VA>:13-<D
M>$V6*FZDQ06@O'[#WF+K\N#A7OX6,3+=A1N>KL7)>M\B]#@.[L:_84QU0?#.
M*@C31.BUC=)'4# ;2/XDXVGCVK8(&HVNFW?TTG^6^4]W!%80MH!E'=V_5#9B
MX6IM6+7E>[A'?X45-"*U$4J*]%#?\T8B7*CMA=NKK=[#;3E0L0PA/K!\#V#R
M6O+&-&]1:>6I_=W#W7BNQ64(X1%09?;[(MB:P#/]9;5J=K$6O5:RVMT]W)S_
M1S;+\P+(6@%QV9. [M&NW'[A>.#V*<M)+%8@1*]Z,'&]_VBP;QB5E1OUI3*P
M[2\/-X(#F^T UU=*F;>&W?M7GVY&_P)02P,$%     @ .$V45I^@&_"Q @
MX@P   T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"
M\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]
MDKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M
M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"D
ML<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#G
MN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/
M\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&
M,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T
M\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]P
MSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=
MD$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL
M?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG
M>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6P
MQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['
MNXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-
M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ .$V45@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  X39160DS#5NX    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  X3916F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #A-
ME%9MYM)"? 0  ,81   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  X3916GZ ;\+$"  #B#   #0
M        @ &_#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #A-E%:7BKL<
MP    !,"   +              "  9L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( #A-E%8<.&7J/P$  #P"   /              "  800  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  X3916)!Z;HJT   #X 0  &@
M    @ 'P$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  X391699!YDAD!  #/ P  $P              @ '5$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"   ?%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20008824x2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://femasys.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName -  ny20008824x2_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="ny20008824x2_8k.htm">ny20008824x2_8k.htm</File>
    <File>femy-20230418.xsd</File>
    <File>femy-20230418_lab.xml</File>
    <File>femy-20230418_pre.xml</File>
    <File>ny20008824x2_ex10-1.htm</File>
    <File>ny20008824x2_ex4-1.htm</File>
    <File>ny20008824x2_ex4-2.htm</File>
    <File>ny20008824x2_ex4-3.htm</File>
    <File>ny20008824x2_ex5-1.htm</File>
    <File>ny20008824x2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ny20008824x2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ny20008824x2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "femy-20230418_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "femy-20230418_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "femy-20230418.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "femy",
   "nsuri": "http://femasys.com/20230418",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ny20008824x2_8k.htm",
      "contextRef": "c20230418to20230418",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://femasys.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ny20008824x2_8k.htm",
      "contextRef": "c20230418to20230418",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://femasys.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001140361-23-019300-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-019300-xbrl.zip
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M9)D@6JI?%X3BH=,1 9SA!B<.JA/:275R@3.-[N] ;M/YRD\Z6B#I:('D+5G
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M?",<C;B/>A)-RP[$&AKJT)""BT%!KND(6P[0X\ KH\!*I<FH9 4.O;%,6E@
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M.?M\T/,2?XH#Z0WS400?_A]02P,$%     @ .$V45M%@^[@7L@  LW<$ !<
M  !N>3(P,# X.#(T>#)?97@Q,"TQ+FAT;>R]:W/<1I(N_'TC]C_@S-G=TXR
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MY BIKU:@\%"[)4M4C@O"5N =<JM-67ZSO=3NQ*3'I#8Z^;7+0?C0ZI@,-J(
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MO.0^>E6]@5O LKKM(E^@_/\,&RZKDQL0?82AP%55EL,]FTW3FE4 :OAY_B)
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MF&I5:T;,A2'^-,NT"7* XI*#]IKE!]1HG4. #KLBD4 7+.3-AJR>!)2@;2H
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MKA+13IRL%JKW")K:A?4+VQYYA^0/+4&;O*>>-[)6QE,DKN"SKF9TE"1RN%(
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M,WS.08+[K_T'0:F.OJ[>.O_>M;7YO89A4;B^!5=I+XO.4 ?G:[DY* <X4FP
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M#WE0^%@9E=R#->\QCS^G!/SLSR^@,YHT*S;)E.BR:8'\4BOK9MY(T9YT4Q*
MV%2DMCVOG-T82<".15H$ZA]X7,:V/V3-K?K3=%'=?+%SV7SKO#L[->3Q"E-\
M)'BTZ/S]GF6+X5J%J!*B_S:..K?K0\28/P[&&$-(O\&OKJEPVL66/U5L^=M=
M;'D76[XED_?Q7X%YW3G;+Y9UF3<$:@*1H&$ _<_&6_G<G+.;X!3_J__W'82O
M_>F/"F=0WRO8+V0NRLK&/*_+QD:*N?01OZ:F+@;<LS\6$&H*;6GPL4K\#'=-
M%!#'=X8)N!),!.#V/RL;P>W1I#J[(\1)4Y"9QHV\QE@[K].I1(]&'(<FP@D;
M^YJH;0:/TG()+<O7B+1UA&(BTN,_W)J4YQD6;65N7G%HWUKQ)OU!]CAZMLZ^
MZBL(LT_>R:)[.MT;(27^J__WJ#4968E%K T#:SZBR?](]KX9)9=N80$%I83H
M*_.^=.ZNB=TJ/H8*N<$&*A,.'BH9'06EII(;H2NN%UO=:..Y0GBF-!YBX'U*
ML>K>%'CK?(8!PQOR$E-H!F+80SGWUI./8^D$HIU<54A!XA II0/^*3K0F <C
MR>CD?8U%5%W."SO/L-36C5[U \ ]9Q!?([Z?DCQW+1B<9<VTSB>F?0R^G\/L
M89P !9>Y1<),.7\U!'4;*Y)YZ(;CW,QDF->'<_]!29Y][:.1VW13@/:&YFWL
MQ.2%>[)[L2V%1%&/>?\_4UW0"WF_N<C@0PH,)KK?#)4JF8QT15![[L^SI69"
MD;^(8S&6K7NH!%63@#Q(GPP$!CMWMZ<8W7AX\.#+$=] 7TY\#@"L+2A##FN^
MD532P(+&'5F:I%D)\-#0'BHU)>9OG%D!C7[N4.Q]_>"G9JD:"%%2IVDA:@*U
M@],R/[H%+[/]BPP@+)UX#X1]X_SS(JM__.))>_'35^YI3T8XI+U%724U[A%<
M/1)TG  UL(LH;+C .8=N-_?=9F3#@%2-$)<_IR,O WF]!F?O[!3JIY.D?"0?
MJ?FO>_-[:[A)KJO$,R@P8/I((<FPK#6R2]9 +J9PX4"PC1-L^%0"4+*U$!H!
MA_*&MH@BYE$Z[A%,.45<),8_<I]AD$MW7;81 LD;'@YZCRP.>+1;?,N/=Y'F
M6L835[-#AC5M-*[*YYK2E$4&]:ZL"UE_!H1#F\< *Y"7*.A-M0JZ ^[DN1^_
MOL&[4,_D+CP5LLFP[@;L:6R6F?,XSZD<H<Z;&$EHF\G)$3=T2OXMO>4X6"J^
MU:-+SCH54&=>EH9%9ON-3VO?VBVXNYQ<?GAP^"76/M'F@MQ L6$+F$3PXT>:
M$<L$/$QN>/-E42 4+!(2!/"M%&/?!,F+EP>*PUL0WZ)2_!4?FN>8*[^"S#R]
M&%U$G&;\$G392!4:[4AD#VYI@/&=@.- X+1:<+Z!W"(%E@[.@X%#"<50L*HX
M9J:"^ J?^Z]E*9E"=_WF.__KGD[W\<'7=\$#VABU/'%RX;SVL4GML.B8AV#?
M4=8+Z2A]2R?\/V&_TU^(O7>Y"HKDDC([KUKLYC=A%[$+I2-V+T1Z$"WZJ+^7
M;40&!,$BH,=#<Y%.!?@&C56'VGD,RE<2K/@T[3/$AUK$QR![-H@[(8Q8@UV&
M&-0:0,RL;V!"<R() R10C?C42)B*W*#9^;)(E17)EDA1KTE0K25DKN%B8%D;
MY8 ]]$1 :24U6F)-,Q2HJ9]<EFAZ]C[*:5.*U6&[&^1N>Q]JR@+,DW?9PMO/
M%GZWRQ;NLH6WIG<?WP7-NE'O6JA;GRE\F5X[5T49R<2]4P+*KE8&5YSS"_Y[
MN$ACQ0_ CD0P.#,H.&7",XF!?@BYX60U5F]^3C@8SSB$1P3<X&2^ #CB[_;_
M;ADDM=TC#:!P//4WQ/&$[KLE@N^QUWV^T]SF9S"4$&,;!$F.Y 6V#4!ED+J
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MEDP'1'<5)AC$+OHFBMC8LGOP;^>'0BB@QVG'E<#AXTF:LK.FOG X>+66S%%
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MT2$MFO/9@7H7)JBU#&!N-C8F)>6\ 3\WQ5AGTJ3@Z<<TV<,H7TV >043T:5
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MIM;;X8EGYY4/9YE4.8<LNIX3<>)\CUDW"Z3=P>XA$!JS[Q,OPLLXS[/05Z&
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M>HR[0)0 6'.5Z:E&NH"T)ZL[R:; ">;KZO'I]NVFRX7*S!2=GXT6=-*D2EQ
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M,M6B@TA027)>B=^8318U.E!RO+A5I=H*=G#_M?EC7@ULC5>O>1PH9#"6W.V
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ME8W,(#D<?9QA4TBI0#G!THIYQ52;*E@UFOP:ZR)/2,@[T!B&R&T TA:3RD7
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MVGP7.[.0I)<1O??S@S>#5V</_ %MUL7T6?1X6NL&-X=%71<3:O>!7G+\AC.
MS2K]MX)1X%O#HDQ4R9_9R^+1Q^@)=+@JLC1Y'EVE27V!P]W^\X.7__6?.S]L
M/W_Q$#XFZV-^<@;PL#F"FYF\X<O!IXMTF-;1DZU'+QX.;WBQ].AO=$/@Q[R%
M&L>3-)L_N^[3[J+2NN/L_/;Z<._P+-K=W.'9P8=N>D>O; !ZNF^RT[_/JCH=
MSU?9[:/!X=GKP4ET]OKP-#H=[+\_.3S[6W1TC+\9Z%\<#DZC5_"K#Z\/]U\'
MC\+/@]\&)_N'I[M[;P;1Z]U?!]'>8'"DY>?)X)?#T[/!R> @^@!-A9_=/3J
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M5+)*%-A;!:I#GHZJ, %FO156'U%9^:#2%>0C,FF$9&LUXQ;O,3+A;0SC(FU
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MV+[CD9_[X8PN.6BBGE[4L*]%)"R'42<Y;"EN;^FWMCF-%LX/N564*F4D/9?
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M1D[MM-V;2X'%?-(S/91#=L79:J"?LZ$<6&GC'':8F+0?VO4Y['R7IMFWT)W
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M+'E&E?PV*;R[N6G]5_2MGQ^@N\08FF(OHDGV3.]_UZ1\C.9-8%0^#OQ6+6Y
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M?OQX^[E]7$\!O$5_VWG>Z^-(X'_V]X]/#@Z/?GOSMW[T=H S>0;S -]^15,
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M?>*GY3NPOMY']@;[?_GMY/C]T<&F_[U'+Z/6&-0M[."'(80?WZH0UFH)-?*
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M:D(EO&,%.FOF;ZE:I7IRCV52*@!U9=?M9SJ)#..VLE8\ATNP3/^ADF5!4?Q
MVEU<3DKTDI*MV^S6@4E45+ZP/<Q3U%.,>UAO8#19UDC=.T?J[FROH;IKJ.[W
M5KIGW[K).,?.%"<A"]_^T56&C,@-2FJ:(J\Q>83' E%S?[?S VS&^H(CS"1M
MVPBNKZ$#WUT1\N.QV O!%)$!.=@Q=FW&$O9Q'5*>UQ"+,:X*H5F%O:B]-VNV
MF <PZ,D-GV)SEH\T0[0%W;.:=8>$B ]Q:]U=7<NO*[3L_B\&G2VEIMU0($M]
MN!CG<GRX $7]4M3L $\&@MO@YUQW"MM!H8$;R/B@8BT8W3.T2=K=BB,P^Z9Q
MFF'18#X+S4H%(=C-,K8Y=&<:RLDX2[=6CWU&7W;F-F@:!$'S<30J4S6A:AQ>
M8 -=([IHC@EIVZ;6RO_=*_\[:^5_K?S?K6R_">$>M:L) PS>6]$(<M11'!!V
M&]2X"8@T8I<^PV6<]:@G*.X'D@_E-GJ #;3;I\! W,6RIA 5C1G->9&7&"!B
M^#Y"(2T39,[I:Z5*U-0+2WE-&=C%?EN+QBLD*(_85%NCC P+@@J_JXE $',F
M?'<</1A58Y@,CB&Q>2/Y/,O)6AV2NU+_NQ2>,@R]2V@<;M(X,]YQESHS\#UJ
MN\;F:DFQMA:\&E^"3>K9YK)I-)F3.UGJG*$P-<NI_&YJ!9KL2"K<A3H#D00L
M^B85DDQ))[R^6CYCORN%S+C<=2!2)R0UUI.R#/V<L7JU%+'A]1OKLLCF>2TE
M'=+<_A/.#DRFT%AD*:R1G=>KE(U7SJBB#3"9Q&ECK4."$\-MH@??%M'79!:Z
MT(?1JH+X<DVS#%NCUEI7DI3H>27^ IMI ):_Y4K42M*).L?Z&<U,&_@L9KS6
MT>-M]#_ <8;7"=;M.4L=+(@P=2#ZP&=N95^T:'@H-2:I2J %0_,K.B*&.A'9
M]LF%1[22"G(Y/(]:T FZ>72T?4_X]1U9U&\1$+1=T#?@M$9 "-OB$JZ29<*H
MF.A/TK?,KG>0RTOZ75W7\7;Z$]S[B[;9U"0L#<8@1W#H5,.^)$#;,Z^!7N;(
M4G!>\'G4B8#G%\-P64%9TQQ(,4F:X32FM?\Q#/&M-JVM]$#M"<1M'R+>FA9!
M$E"BRG$,LO<^;R8]8J76"7W>4O )Y$HVYT765I=;$TBD*]?'X8A6FK,LX_7G
M=Q;\)W::"2=,/-'O8%P:A+^%>E@**0F8!!5%S7$V>#_N3FL54>P?_]G@+/0H
M=<T;+9:H-%%:SVMA89?J.!7&%&%WPQU#98DW!:664@FB6'J(H2<=<0_ _P;!
M8B^Y-ONV2I%7/<Y5,:\05(F$".YDM]0']$WJ:)^S8T"^4EE!^/LK#+;_O/D7
M@G#I"?#";XS<"_:OJ(+>[#31DHCI5OG8 19J<)G;;4U:Y(MGF1/.. *)<WZN
MK/4K;RI3$1@=PY;W#(_;)ZR!B]-DBP5+]/&!>7WNTHMZUU5FGI")<AL.5325
M=-U+:RE9/\^ZRLP#\"+?0I49O:?B$2'[O:#;J:TV'-;J)@B'57H=_O0LOJH,
M4&2,F$0.V'DUU,UY0?"IW,3T3M&"JS /;^UH*6T(C <:G=IO I+H,F$5T6+U
M5J"HM)8H&@62C,0?ZK&":>9,"C1?(1!;M PT$_M:*<+;KZ4PG0:I@@V1(^T<
M&HD34Q;#NZ[1J,'2>N<YUT@^Y['Z]:<-UM2R\32:] U3-W$MKNL8:Z5'/K=;
M,L\(MS2>UPW(KG2,>D-*!9R5,E>,SF%(N8-H(8:]!:?-:F6OCC^IRE3U,0;9
ME%&2^L;6CPOVCD&,9E9CM _2B='&!,<H8/DVC4:&0]W4ZF,<Y7  35ZID:X?
MM$TA<X4 (V/?TCPKUC?EYXI"Q_90L)9O]$ZI\2(FL_OOJD5_=$##>#0<DB5;
M1X3YV+4%2H\4X7 $DVSTI(YL6M1_*[/R,J)$VRF-.BTF\('E,U$H9!E6:>E,
M[Q8UO)'EW8!>"3>CJU[/+A85UA!%S<JLO-<GO_1G-,\)<.5\&P%6>DP!U!0L
MYWE&6;D^[K>#=G6U'IA$"<Q(PZPH)[W%R8US+5&G)=F7%657V_-,1S5HB/\<
MUD_6H^(L"9--FTYL64XS&TZ)4YLV@,O%V>R2ZFAS=0G9CAM,>#P<OX,FU0HC
M3UK*7L27G-SE[D\&'JQ#2G<?4GJ\#BFM0TK?6]VB(RMJ?#S9F2LO=5'EE+TP
MY&BA0GN2(\+.+Z,/D+*"UCX":>DZU1JL%#U#LN@*<]I;M;IN[4U[@$D;6.@[
M&_6.2C065VDPB6N./'4=H"Q:03*PI&<%+O"X=.EQ6\MT?ZN\Q[V^L-IXNIU7
MJIJ"")>.:J.KE=EYCIM$+JNK:YZ>%J1QJ65JG;B)6Q:])8G.<^HA&-&VRM Y
MU%]E_)5+XE=9CVRBZ=2C0]+<#HS;*3!<S!NHNU$!=>UJ<QZTOJCKH!^:QLGA
M?!$7'2O\:RS6 QCT+=3(D&UFO5$ZBL9Q^K/&<2YUE,VG>2%YRN$+?2K1 RPL
M @'M*A_LN#:1KB ?-XSH^0496DPYB9MH4X$E.5,74 6Z@O[?'PZ*-D3SLGV$
MC NN;-7#5.:KC4/.YDD\HI"J8LIXTW8SE.>1;\EC.M+14N5!9[N2,8[/812:
M SB"8>YCVP0M&]=S0B^XGG%MH*T%PP,8]"T0;C?]U"<*=^G8XOHUW39N-SIG
M.N^UTV76 0=Q(1A-VM*NOP:E(%(Z')B?Y9Q='QSJA(L\OZ!%3^J,!(4*4E"]
M>C#FFYV?<1VG^'I0?G*$2;'5QP6[4G46%Z@_YZG.^4;],E/&M$:8QE0J""'W
MX68QV:0'2F?>2<61>%QKP)!\+LTRG2=S^-#.DR>^@H8B4%YAOY?U]0H:AOA7
M;$ZMX\W3M?\\?Z+^HVIAH&VF9/19*UUT41QH'?7IUD_=/N.U?'L @[Z%+*43
MY5I___HO5LYY7G*K!ND+6?[,].O&U590V2KY)%MZ%JE'Y&J$!K'LP*'!T&^A
MZ-0?)EH870',M8@"XZ"%A)G9G"G=]2HWG 78/<UU"*?^,E573I8L$P8Z6@DZ
M\TE>J2PSX?2@#Z+*8.3$X#) W%^F1>9!_*Q<)8$JKRV3IB!!^]I2\K@38B3.
M<80]66P(+%))JR#'!M=>RKOW4NZNO91K+^5]0'H\O56DQ]NTPJ :0Z_6T(X'
MH*;< K3CJ-#%N&WYEXAQGA*]>T]%WW2BQ?,(WCA5=9VQ00-7\'Y<76@UQD7>
M%8H!P0+2<U5Y<09+70N=&:#QO)4%DY:Z;[JVB%\:(. FT3A*WPD2=^!*'F\D
M/3#G^M9+:O'U39R>\^+N5O3!185(&-M C1$3;0>JB7A#?2:W]3D00$OQ:-UU
MS7/CJB.VVV,J\.I\F@"X@FBH.EZBL9)BYO_NLB>1=W)\Y06#&_V$<G>J@\A[
M#A-$S5>T)SRJK,!$6UM2#V#0MQ"?>U-4T""82!-;GRN*#M!K,1]KK,Q;9(8U
MAH"+=_2<LN,"=K<UFK176:6P"F'MKHDAZUM&7VB+9&;4SYKZB7 LMWM3KWL^
M27UITY] D2YKAL9KTC=#A17R+)T*/8, B,8"K'!ZP1@BTX\^91G!PD]SH5 R
M;(7+Q\?,UL8QKEMR#,6^XRMC[)P2*%%5"U2+9$>1)T*E%6#?\%<"$C*SY%F!
M-C;7F"A"K<@$8RS31]E KZ1B]I+P8'/R<2;3CTBU1G@I?)FQ=97IFMM?FIPL
M5?.6CC>_OI:$#V#0MQ!,.XWK>8F)98X</$6Z+O@-:API_Z3JL<F")<&$N6D%
MN921'TTE1)NM0TBU05.2H\2(+%:E9FEI#J31<:P&4)2<9BK T#3WG>:Q1_DK
ME6B8*H#;T33YE)\F_,+21@-6)NC/'%;-\1CKXL%N0^OS]0 &?0LQJ8%AU7/.
M%UVS:SJ:;YN8M-J0=VYVP-V*8E_RR-RJ6)).YKK+P]J_:<T*"'JV2UV+A;!4
MEKZ1(WX"$/(9DEUX?(/!"U'/G!+82O78XL4W^'G70"/K60>]Q(!M<LAZB7@&
M9<$%7D*=.A6\D^U)(Z1J4Q8)@ZRGHQ:%LQ),7(D5-PM"JT'_RG,-M2-D])PS
M+[$E X)32 B*B>BKC-Q#)"\?>4CY3HM:DU9)>&]*:S6DY)I=N=)7F.V7<+WK
M8I=M<0Z-B!.RM<HF?LH%:^*Y;N0CB'%D\15'5,[G6C]UB!C<(&[AU\AX&Y<?
ME=A%86E:D_%#NU/ZF6%P)%EJ9,46"6?@WA[XCX>Z\B*9,)@&_K@$Z"D"]5L8
MQ#_O,UP^:J$Q]5[9@S VEK>CXA'+A\DQ]JCW.648$VL$=8F;?Z$K&V'$+$<"
MB*HRK.A4KH9IFVG'?4+Q!69&SA% /A55-*9Z+@T8E%^144L(9<)G&^QC@T7*
M)=7&?\.%3AC&[['A+RFHGD51FMQ?"X*D=GKK6-C=Q\*>K&-AZUC8ZAK5C2N1
M0_&MV[Q-H3FPWO:KF&JM"?\\"V1$>+HPB3;@-]F8"\=J=>HF=N1M3J6B$.H8
M@;<'7O7K*=<793$_UWQ"?M%QC]-'.'LZ:"P\3AR6OWBAQ)E;1<C'=EDR*DNM
M8VI2(#DY^^[41](GZ!<X.\4(M<Q8N/Q!/27<EE-_0"X!I#RI0LT,+JRY:*MR
M9=>TTG CG!>@YDYB@G)4%=SWUA%8EI2!@/,L[$:,X:(6G,Q&Q\<@S]B,,L:=
MM6E+[++0-8U%XZTU_X:-MFAVGR#.X]_HY\B)@74CX+HM"=C5#.+@9\]5CK3Q
M#K$'9FJ<%[2I&JY%C*F(TQ,U0/%ZQJ5?.3BD61P5ML0P87VX/JI.=*7[&=6.
M56N>2S:H=('SB[D'?2FAY.FJ2Q348,J)%B71E2U#:)]69W"A,W7..<.TPY<J
M-@$D?+F.'BAE,!H8#E(^$8U'.>9,94?[5A/< &0?<9$Y9]RBBL5"$\1@'@-[
M9.%3Z3(9"PV %"T:_>&C(EGH',4_X,16">,FM4K5MY/:]]5^E>NE#8T)W-9\
M5MGT<2HPM)@C]]D<?X >B!L?\AX>?",P'8\LF4SFRBSF62)4KV2!Y"[-JTY@
MZ,KU0=&BC3L7/.V7C;)\2#[_;-M5O/RD6> <_<N<%??029I1OU4JZ1-IDY-:
M#R;"HHL$+]$E1W1]@KY[Q^4MH'G_R]E)C9H#5'22MC;6>E=EKG4)\G.9Z*LF
M#(.+!R'U4BB2M230F&:P_]LCQ#8YT-+5K5C#;XUH?Z!GX-88^QM9.C9;VO)L
MCC_FQ56FDG-56=4QU(+'$D.\5O.C #]JV1:+;>MQ:4(,C3;C"L&,B?(P50)S
MEP+?3LJ+@$ H%P;,@T(H+!@G3EXXA?5-LY# :'V.'L"@SV\#<IF3R\-)?<-=
M-OPT4Z ,2>K;$:;4STL^#(F*,TF28.+*+"9MQ^&Y-&?'!NDMGY6<+\J=L/:R
MJ&XS50JS:,RNF-)@6/@[&HQYQ44<U1_SA/) +YKUEP7(2?7J*HY H+FJJ@[$
M)'W78[ALK1PH\:TV0J^@8AP><38^<4I1"D%32$L),U49GH*%30WL;+0O*C(K
MV>SG)[N7.36C))[&YZH*TVF;NC&R6ODTQ*PBD\WOPF[-->^S8F$T1=-!5Y+Z
MHV2ON XO]-^@ *0))A=:WXM*"6M#):L%4HV*^^2F[L^%3B2>S0C61-J$P"OX
M281KA2Q?E'*995*YDPP6&5DR5Q:+*F4#V:BPVXDU(;=:A:77[MY-=FNO9? #
M&/3%;<A@S&4/RH<9SMV^J21O@.B)U*[TH$\SU,9KP^0L!;F*TF$B;U1[:0H(
MC[E<,[4)+[D.[6LX.<53B9_<4,XYI5%)"(?D!NLC\@ &G=Z6NO_&A$\\0MDW
MJ<L%BMJ*O4BU>T?V)Y%(V"!$#'<;I9-?&J2$?Z%T4CFCHU1K &T@:,Q=R.&0
M2@A'TWI/O&@!\I.GEVFFSBVYN;Z[^3B>4_I^RE4%N+2XC-4)V#C];;#;<9UK
M&:[/P%Y>E\G2-X5824DP35-N;U5Q/8<0J$YR90S2(X4K/JRGL ["WWT0_NDZ
M"+\.PM_I_?#'[;F#6"7O< 71+0#*3*JIAT8*S816WGZ'BEECRD<+SLZW5@HR
M,5%M!C2+V003QTY0SD+H<L=A(-Q:%M>A_:(8S4QQ8($05USC1NP^#L%HG'L"
M6J%3AQ6M3##0^"*:B-F.F3F>%<76&><+CDJJ=@._M0E%+97#W5BHU/[1O2S8
M>C?<"XPU5$R70,4N<@X..T$EPK:U310KFFQP+:C 37PE0W:&NU8M'\"@/]Y"
M'@NF;505*"N^"VQ C,/B 7/();M)Y%L8W1UMCTH5._%TG<]GSHYP9.?B1,-7
M1RI7DU3PC[3;1Z9RE?C1*M-]!HH:*Y 9DQO5RW2O_/>,VZOM=9:>+(Z6B8%2
M4? H3XP-JM51;QP+HZR&G'7+N24E4$4SWR!WMPJLKXVOI<(#&'1V6PK% #%Z
MZ&FYEHIW6B3,AX_WZY3/@+;%[)$1K+. #$V@5-/I"@"A88;)48=;/[H@]J0@
MWM3P%NL7R'C#5];'X $,>GICQX!H8R[;:ZQ\P$V,48 9J) IE8T@;;$[8F+9
M@36TP"%79OX_804>N46N<),33*%)0DAZ.,88TLGRP(EM&QZY2$>I*/)<*W+)
MQ[DNA_DL?4;/ (W$]M.'$NMPE6Y/ +S2&B$N-!I8?A<;N"<7$DN<H)=[W9;.
M,_A&]U6\/NT/8-#YS:O"KQ4E7C7MYPOY X)=FT7_4/'3FAX5>LU3[60M%1)D
MTC]RB8,:O'S?&*-"\LMY2AA,3:1Z[7ICW]W&]@?<ZL/\JK']GY;_?)\C_9Y7
M\47Z<N.4:GVAV8I^X^A5@52Z5>_%#^G+%Z-2-S/.5%RR-];XTM?1@+N.!ORX
MC@:LHP&K$B?>,,7!X1&LY=G1\/0T^O!Z>#(\?N5#EBXL'(DJJP>ET,1><.K]
M.=GZC+"?8['Y(/-96)/(#XVXHDE:5C6G02$A%>7@W96]O/(BW/,MHOM5DT&%
MQ%35+$9DU:^/MA_1OV<8AY%_2]^OTJ2^T.=Z]8&,*"EL$W%?\:R"S:5_TL+(
MB*3:W$67F&XYCC,]%I@%*[KPR<3,,/SH_<';^<YNQF9AD/FOCQ[?Z/TZ>OEJ
M^'9P^K?3Z/!H'[;EZ*79FD[7X!_ERSL8:,O+W[ K-YGJM'C6-J_+FC=;3Q^9
MO2P>?XQV9EB9$NSZ&YZ=X)@\W?YS:P/+>ZQ?_HIWG^#+-S?Q1_%4M4[]M]Q'
M=[CQSC!(?-T$L))!TG2M*=^1IOS36E->:\K?Q*0>O3PZ/CO<'T;'KZ+A7X<G
M^X>G0^_B_ZZ&V^X=^2S-\0O'WSYZ1PW]*@TRN*^W63'NNF'T4TU7(R[#S<VW
M?)LY0T"T/8OFLYDJD487[J*B6PGZ-CU =5=-XVI118?Y>!5UM_MJ_/:VT/?I
M-/PFOH"-'2^<05$'BLQ),5C!R"C,[3%> 1>$_;_RGP:U?4#.[_#1!_PSE)84
MCR^@-?V-#8I:I!.'^%5*E0MS-*%=RLI0K1FB-OFBP1,R#MM4;P\*ZB+1C0U
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M0.)_GQ[^=C0X>W]"4?37QV\.AB?_<Z^FX5Y>0O>C%_^\L-&P4S_]N0W@$1Z
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MP232ET+\.!E))"Z7O1P#K076M"<]427=K2C;(Y$-2L*54NEY5*SK/3^74/P
MJ= ]F!6<A7SH)9_ZXRL6*_F;G+[ .<_V%Y[$]MU8(C2,'F-8^OO7Z*,[PMST
MDX8%GQ]X+IUT3I1.DXE,Q.+,LXJ7WVKTV6$G-$V;*(8LN/1 POA0PSXNM3#B
MVU<[U&"'[@B/15(#]-)U4BO?8R2%74'DL)1NPBGT6=VWD0V@.)D; =9]?AG,
MDH;,D<.L3*6=^F9'Z /5RJR5,VN/^FGDK'\QAS-;M:; US]*$;@B70R@-M@
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M(E#W5#)U'\(_QO$?4$L! A0#%     @ .$V45K ''2-& P  -@\  !$
M         ( !     &9E;7DM,C R,S T,3@N>'-D4$L! A0#%     @ .$V4
M5IW"%?*X"   7UL  !4              ( !=0,  &9E;7DM,C R,S T,3A?
M;&%B+GAM;%!+ 0(4 Q0    ( #A-E%8M4>L:_P4  .U    5
M  "  6 ,  !F96UY+3(P,C,P-#$X7W!R92YX;6Q02P$"% ,4    "  X3916
MA5Y<?\<9   ;HP  $P              @ &2$@  ;GDR,# P.#@R-'@R7SAK
M+FAT;5!+ 0(4 Q0    ( #A-E%;18/NX%[(  +-W!  7              "
M 8HL  !N>3(P,# X.#(T>#)?97@Q,"TQ+FAT;5!+ 0(4 Q0    ( #A-E%;H
MP9IHKD   ).= 0 6              "  =;>  !N>3(P,# X.#(T>#)?97@T
M+3$N:'1M4$L! A0#%     @ .$V45O[3M<X02   Q,4! !8
M ( !N!\! &YY,C P,#@X,C1X,E]E>#0M,BYH=&U02P$"% ,4    "  X3916
M\=")>Q%(  "3U0$ %@              @ '\9P$ ;GDR,# P.#@R-'@R7V5X
M-"TS+FAT;5!+ 0(4 Q0    ( #A-E%8O+Z<DU P  *LR   6
M  "  4&P 0!N>3(P,# X.#(T>#)?97@U+3$N:'1M4$L! A0#%     @ .$V4
M5H@?Q-"3#@  E4,  !<              ( !2;T! &YY,C P,#@X,C1X,E]E
?>#DY+3$N:'1M4$L%!@     *  H H (  !', 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
